JPS62252762A - Pyroglutamide derivative - Google Patents
Pyroglutamide derivativeInfo
- Publication number
- JPS62252762A JPS62252762A JP61280453A JP28045386A JPS62252762A JP S62252762 A JPS62252762 A JP S62252762A JP 61280453 A JP61280453 A JP 61280453A JP 28045386 A JP28045386 A JP 28045386A JP S62252762 A JPS62252762 A JP S62252762A
- Authority
- JP
- Japan
- Prior art keywords
- value
- carbonyl
- pyrrolidone
- melting point
- elemental analysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WGOIHPRRFBCVBZ-VKHMYHEASA-N (2s)-5-oxopyrrolidine-2-carboxamide Chemical class NC(=O)[C@@H]1CCC(=O)N1 WGOIHPRRFBCVBZ-VKHMYHEASA-N 0.000 title claims abstract description 5
- 125000003277 amino group Chemical group 0.000 claims abstract description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 13
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 9
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 45
- 238000000034 method Methods 0.000 abstract description 39
- 125000001424 substituent group Chemical group 0.000 abstract description 9
- 150000001412 amines Chemical class 0.000 abstract description 8
- 229910052736 halogen Inorganic materials 0.000 abstract description 5
- 230000002152 alkylating effect Effects 0.000 abstract description 2
- WNISGGBLKVYPLT-UHFFFAOYSA-N 5-(4-benzylpiperidine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(=O)C1CCC(=O)N1 WNISGGBLKVYPLT-UHFFFAOYSA-N 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- 238000000921 elemental analysis Methods 0.000 description 107
- 238000002844 melting Methods 0.000 description 106
- 230000008018 melting Effects 0.000 description 106
- -1 pyrrolidino, piperidino Chemical group 0.000 description 32
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000000044 Amnesia Diseases 0.000 description 7
- 208000031091 Amnestic disease Diseases 0.000 description 7
- 230000006986 amnesia Effects 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000001777 nootropic effect Effects 0.000 description 7
- 229960002195 perazine Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- 102220587327 NEDD8-activating enzyme E1 catalytic subunit_H21N_mutation Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
- IHJBZKHWJDRTHU-UHFFFAOYSA-N 5-(4-benzoylpiperazine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CN(C(=O)C=2C=CC=CC=2)CCN1C(=O)C1CCC(=O)N1 IHJBZKHWJDRTHU-UHFFFAOYSA-N 0.000 description 2
- MDMAUEITTFGEIK-UHFFFAOYSA-N 5-(piperazine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CNCCN1C(=O)C1CCC(=O)N1 MDMAUEITTFGEIK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 102220523035 Transmembrane protein 44_H24N_mutation Human genes 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 229960000793 aniracetam Drugs 0.000 description 2
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- JEOVABNPJMHXGZ-QMMMGPOBSA-N (2S)-5-oxo-1-piperidin-1-ylpyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CCC(=O)N1N1CCCCC1 JEOVABNPJMHXGZ-QMMMGPOBSA-N 0.000 description 1
- YQXLOVXVWICTBX-ZETCQYMHSA-N (2S)-5-oxo-1-pyrrolidin-1-ylpyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CCC(=O)N1N1CCCC1 YQXLOVXVWICTBX-ZETCQYMHSA-N 0.000 description 1
- IGUYYHAFNYFSEJ-GFCCVEGCSA-N (5R)-5-[4-(2-morpholin-4-yl-2-oxoethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1COCCN1C(=O)CN(CC1)CCN1C(=O)[C@H]1CCC(=O)N1 IGUYYHAFNYFSEJ-GFCCVEGCSA-N 0.000 description 1
- ZNGHTCSIUZKPCF-GFCCVEGCSA-N (5r)-5-[4-(2-morpholin-4-ylacetyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)[C@@H]2NC(=O)CC2)CCN1C(=O)CN1CCOCC1 ZNGHTCSIUZKPCF-GFCCVEGCSA-N 0.000 description 1
- XUYNAPRWJJVFDM-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-[4-(2-pyrrolidin-1-ylethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound OC(=O)\C=C/C(O)=O.C1CN(CCN2CCCC2)CCN1C(=O)C1CCC(=O)N1 XUYNAPRWJJVFDM-BTJKTKAUSA-N 0.000 description 1
- RYFCMEATCUQTPC-UHFFFAOYSA-N 1-(5-oxopyrrolidine-2-carbonyl)piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C(=O)C1NC(=O)CC1 RYFCMEATCUQTPC-UHFFFAOYSA-N 0.000 description 1
- LISKJKUMLVQGKE-UHFFFAOYSA-N 1-morpholin-4-yl-2-piperazin-1-ylethanone Chemical compound C1COCCN1C(=O)CN1CCNCC1 LISKJKUMLVQGKE-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- HNSWIGVJTGWTHR-UHFFFAOYSA-N 2-[4-(5-oxopyrrolidine-2-carbonyl)piperazin-1-yl]-n,n-di(propan-2-yl)acetamide Chemical compound C1CN(CC(=O)N(C(C)C)C(C)C)CCN1C(=O)C1NC(=O)CC1 HNSWIGVJTGWTHR-UHFFFAOYSA-N 0.000 description 1
- NDLBAWLHCCJUKI-UHFFFAOYSA-N 2-[4-(5-oxopyrrolidine-2-carbonyl)piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C(=O)C1NC(=O)CC1 NDLBAWLHCCJUKI-UHFFFAOYSA-N 0.000 description 1
- IKOKHHBZFDFMJW-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2-morpholin-4-ylethoxy)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCCN1CCOCC1 IKOKHHBZFDFMJW-UHFFFAOYSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- FSJZLJPBIQBXTB-UHFFFAOYSA-N 5-(3,4-dihydro-1h-isoquinoline-2-carbonyl)pyrrolidin-2-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1CCC(=O)N1 FSJZLJPBIQBXTB-UHFFFAOYSA-N 0.000 description 1
- AKZVUJJGPBLNEU-UHFFFAOYSA-N 5-(4-acetylpiperazine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CN(C(=O)C)CCN1C(=O)C1NC(=O)CC1 AKZVUJJGPBLNEU-UHFFFAOYSA-N 0.000 description 1
- IOIZOKOYRPQIMO-UHFFFAOYSA-N 5-(4-benzhydrylpiperazine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C(=O)C1CCC(=O)N1 IOIZOKOYRPQIMO-UHFFFAOYSA-N 0.000 description 1
- UGWACYOHACFGOY-UHFFFAOYSA-N 5-(4-benzylpiperazine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CN(CC=2C=CC=CC=2)CCN1C(=O)C1CCC(=O)N1 UGWACYOHACFGOY-UHFFFAOYSA-N 0.000 description 1
- DBOVLSFOWGQEEH-UHFFFAOYSA-N 5-(4-hydroxypiperidine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CC(O)CCN1C(=O)C1NC(=O)CC1 DBOVLSFOWGQEEH-UHFFFAOYSA-N 0.000 description 1
- IAKYXIBUSFZEGB-UHFFFAOYSA-N 5-(4-methylpiperidine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CC(C)CCN1C(=O)C1NC(=O)CC1 IAKYXIBUSFZEGB-UHFFFAOYSA-N 0.000 description 1
- ROCRRDYGWLIXBS-UHFFFAOYSA-N 5-(4-phenylpiperazine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CN(C=2C=CC=CC=2)CCN1C(=O)C1CCC(=O)N1 ROCRRDYGWLIXBS-UHFFFAOYSA-N 0.000 description 1
- MLAAAANVVPHUOL-UHFFFAOYSA-N 5-(4-phenylpiperidine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CC(C=2C=CC=CC=2)CCN1C(=O)C1CCC(=O)N1 MLAAAANVVPHUOL-UHFFFAOYSA-N 0.000 description 1
- HNACDIWTXLVJHM-UHFFFAOYSA-N 5-(4-piperidin-1-ylpiperidine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CC(N2CCCCC2)CCN1C(=O)C1CCC(=O)N1 HNACDIWTXLVJHM-UHFFFAOYSA-N 0.000 description 1
- XWJUMPJFJJLJNS-UHFFFAOYSA-N 5-(4-propanoylpiperazine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CN(C(=O)CC)CCN1C(=O)C1NC(=O)CC1 XWJUMPJFJJLJNS-UHFFFAOYSA-N 0.000 description 1
- RIUFRZNZOQTOOD-UHFFFAOYSA-N 5-(azepane-1-carbonyl)pyrrolidin-2-one Chemical compound C1CCCCCN1C(=O)C1CCC(=O)N1 RIUFRZNZOQTOOD-UHFFFAOYSA-N 0.000 description 1
- FSTXETIGWBGVMD-UHFFFAOYSA-N 5-[4-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(CC=2C=C3OCOC3=CC=2)CCN1C(=O)C1CCC(=O)N1 FSTXETIGWBGVMD-UHFFFAOYSA-N 0.000 description 1
- KMNNAMKHAOPELQ-UHFFFAOYSA-N 5-[4-(2,4-dichlorobenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound ClC1=CC(Cl)=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 KMNNAMKHAOPELQ-UHFFFAOYSA-N 0.000 description 1
- VASBUIDICQIINV-UHFFFAOYSA-N 5-[4-(2,4-dimethylbenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound CC1=CC(C)=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 VASBUIDICQIINV-UHFFFAOYSA-N 0.000 description 1
- LHCJYOFDZWIOBL-UHFFFAOYSA-N 5-[4-(2-chlorobenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound ClC1=CC=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 LHCJYOFDZWIOBL-UHFFFAOYSA-N 0.000 description 1
- IIGFRCNOTWWJGY-UHFFFAOYSA-N 5-[4-(2-chlorophenyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound ClC1=CC=CC=C1N1CCN(C(=O)C2NC(=O)CC2)CC1 IIGFRCNOTWWJGY-UHFFFAOYSA-N 0.000 description 1
- UVWOHQOKXQOQSQ-UHFFFAOYSA-N 5-[4-(2-hydroxyethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(CCO)CCN1C(=O)C1NC(=O)CC1 UVWOHQOKXQOQSQ-UHFFFAOYSA-N 0.000 description 1
- BKHGHAJVGVBDBE-UHFFFAOYSA-N 5-[4-(2-methylphenyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound CC1=CC=CC=C1N1CCN(C(=O)C2NC(=O)CC2)CC1 BKHGHAJVGVBDBE-UHFFFAOYSA-N 0.000 description 1
- IGUYYHAFNYFSEJ-UHFFFAOYSA-N 5-[4-(2-morpholin-4-yl-2-oxoethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1COCCN1C(=O)CN(CC1)CCN1C(=O)C1CCC(=O)N1 IGUYYHAFNYFSEJ-UHFFFAOYSA-N 0.000 description 1
- NJXNTDNNCUBXAK-UHFFFAOYSA-N 5-[4-(2-oxo-2-piperidin-1-ylethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CCCCN1C(=O)CN(CC1)CCN1C(=O)C1CCC(=O)N1 NJXNTDNNCUBXAK-UHFFFAOYSA-N 0.000 description 1
- NPTIKHBPOQKTIF-UHFFFAOYSA-N 5-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CCCN1C(=O)CN(CC1)CCN1C(=O)C1CCC(=O)N1 NPTIKHBPOQKTIF-UHFFFAOYSA-N 0.000 description 1
- HQYBYAAQJMRRKD-UHFFFAOYSA-N 5-[4-(2-oxo-2-thiomorpholin-4-ylethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CSCCN1C(=O)CN(CC1)CCN1C(=O)C1CCC(=O)N1 HQYBYAAQJMRRKD-UHFFFAOYSA-N 0.000 description 1
- HUKCAMPAFBUWHU-UHFFFAOYSA-N 5-[4-(2-phenoxyethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(CCOC=2C=CC=CC=2)CCN1C(=O)C1CCC(=O)N1 HUKCAMPAFBUWHU-UHFFFAOYSA-N 0.000 description 1
- IBCVHGPTFGHLSW-UHFFFAOYSA-N 5-[4-(2-piperidin-1-ylacetyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)C2NC(=O)CC2)CCN1C(=O)CN1CCCCC1 IBCVHGPTFGHLSW-UHFFFAOYSA-N 0.000 description 1
- YSPPUFHSWPTYKV-UHFFFAOYSA-N 5-[4-(2-piperidin-1-ylethyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(CCN2CCCCC2)CCN1C(=O)C1CCC(=O)N1 YSPPUFHSWPTYKV-UHFFFAOYSA-N 0.000 description 1
- DOQWVKIUBKKTSJ-UHFFFAOYSA-N 5-[4-(2-pyrrolidin-1-ylacetyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)C2NC(=O)CC2)CCN1C(=O)CN1CCCC1 DOQWVKIUBKKTSJ-UHFFFAOYSA-N 0.000 description 1
- BSJIRKUPILRBRO-UHFFFAOYSA-N 5-[4-(3-morpholin-4-ylpropanoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)C2NC(=O)CC2)CCN1C(=O)CCN1CCOCC1 BSJIRKUPILRBRO-UHFFFAOYSA-N 0.000 description 1
- RFSLTYPWDLQZBC-UHFFFAOYSA-N 5-[4-(3-phenylprop-2-enoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)C2NC(=O)CC2)CCN1C(=O)C=CC1=CC=CC=C1 RFSLTYPWDLQZBC-UHFFFAOYSA-N 0.000 description 1
- LGLJLBJEXVAYMI-UHFFFAOYSA-N 5-[4-(4-acetylphenyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(C(=O)C2NC(=O)CC2)CC1 LGLJLBJEXVAYMI-UHFFFAOYSA-N 0.000 description 1
- XMGXQPVSRWPVRN-UHFFFAOYSA-N 5-[4-(4-aminobutanoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)CCCN)CCN1C(=O)C1NC(=O)CC1 XMGXQPVSRWPVRN-UHFFFAOYSA-N 0.000 description 1
- WPHZYSYDUWEVGX-UHFFFAOYSA-N 5-[4-(4-chlorobenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 WPHZYSYDUWEVGX-UHFFFAOYSA-N 0.000 description 1
- NUABEVGQIIOGPG-UHFFFAOYSA-N 5-[4-(4-chlorophenyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(C(=O)C2NC(=O)CC2)CC1 NUABEVGQIIOGPG-UHFFFAOYSA-N 0.000 description 1
- DDHFMUFPFQWZSE-UHFFFAOYSA-N 5-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 DDHFMUFPFQWZSE-UHFFFAOYSA-N 0.000 description 1
- QLHHLQKZVNEWEI-UHFFFAOYSA-N 5-[4-(4-methoxybenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 QLHHLQKZVNEWEI-UHFFFAOYSA-N 0.000 description 1
- IHFMEPWMGSZTAK-UHFFFAOYSA-N 5-[4-(4-methoxyphenyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(OC)=CC=C1N1CCN(C(=O)C2NC(=O)CC2)CC1 IHFMEPWMGSZTAK-UHFFFAOYSA-N 0.000 description 1
- MEGGLDUKDVEZML-UHFFFAOYSA-N 5-[4-(4-methylbenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 MEGGLDUKDVEZML-UHFFFAOYSA-N 0.000 description 1
- RKOLHIMNEWIGFW-UHFFFAOYSA-N 5-[4-(4-nitrobenzoyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 RKOLHIMNEWIGFW-UHFFFAOYSA-N 0.000 description 1
- XFZINNVXBANDML-UHFFFAOYSA-N 5-[4-(morpholine-4-carbonyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)N2CCOCC2)CCN1C(=O)C1CCC(=O)N1 XFZINNVXBANDML-UHFFFAOYSA-N 0.000 description 1
- CEPOEHAZMPSVSF-UHFFFAOYSA-N 5-[4-(pyridine-3-carbonyl)piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1CN(C(=O)C=2C=NC=CC=2)CCN1C(=O)C1CCC(=O)N1 CEPOEHAZMPSVSF-UHFFFAOYSA-N 0.000 description 1
- WMAYCIQKYWIURF-UHFFFAOYSA-N 5-[4-[(4-chlorophenyl)methyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1CN1CCN(C(=O)C2NC(=O)CC2)CC1 WMAYCIQKYWIURF-UHFFFAOYSA-N 0.000 description 1
- JIICDYRNQKVXFR-UHFFFAOYSA-N 5-[4-[(4-methylphenyl)methyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1CN1CCN(C(=O)C2NC(=O)CC2)CC1 JIICDYRNQKVXFR-UHFFFAOYSA-N 0.000 description 1
- VDXQJKGFWCCXRL-UHFFFAOYSA-N 5-[4-[2-(2-chlorophenoxy)ethyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound ClC1=CC=CC=C1OCCN1CCN(C(=O)C2NC(=O)CC2)CC1 VDXQJKGFWCCXRL-UHFFFAOYSA-N 0.000 description 1
- DJOPHHNYQHHSFJ-UHFFFAOYSA-N 5-[4-[2-(4-chlorophenyl)acetyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1CC(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 DJOPHHNYQHHSFJ-UHFFFAOYSA-N 0.000 description 1
- XZMSDEXKKMPLGW-UHFFFAOYSA-N 5-[4-[2-(4-methoxyphenyl)acetyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(OC)=CC=C1CC(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 XZMSDEXKKMPLGW-UHFFFAOYSA-N 0.000 description 1
- RJUXZEIMHUPENP-UHFFFAOYSA-N 5-[4-[2-(4-methylphenoxy)ethyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1OCCN1CCN(C(=O)C2NC(=O)CC2)CC1 RJUXZEIMHUPENP-UHFFFAOYSA-N 0.000 description 1
- VFKWKOAWCWXKJA-UHFFFAOYSA-N 5-[4-[2-[4-[(4-methylphenyl)methyl]piperazin-1-yl]-2-oxoethyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound CC1=CC=C(C=C1)CN2CCN(CC2)C(=O)CN3CCN(CC3)C(=O)C4CCC(=O)N4 VFKWKOAWCWXKJA-UHFFFAOYSA-N 0.000 description 1
- GGUYJQLQOVMMGG-UHFFFAOYSA-N 5-[4-[3-(4-methoxyphenyl)prop-2-enoyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(OC)=CC=C1C=CC(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 GGUYJQLQOVMMGG-UHFFFAOYSA-N 0.000 description 1
- HNEHHUXARMOTEE-UHFFFAOYSA-N 5-[4-[3-(4-methylphenoxy)propyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1OCCCN1CCN(C(=O)C2NC(=O)CC2)CC1 HNEHHUXARMOTEE-UHFFFAOYSA-N 0.000 description 1
- YBSXLDLQTXKHAT-UHFFFAOYSA-N 5-[4-[3-(4-methylphenyl)prop-2-enoyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1C=CC(=O)N1CCN(C(=O)C2NC(=O)CC2)CC1 YBSXLDLQTXKHAT-UHFFFAOYSA-N 0.000 description 1
- WSHHNOBAQWKRPQ-UHFFFAOYSA-N 5-[4-[3-(4-methylphenyl)propyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1CCCN1CCN(C(=O)C2NC(=O)CC2)CC1 WSHHNOBAQWKRPQ-UHFFFAOYSA-N 0.000 description 1
- UWQPTPXCKMIZQJ-UHFFFAOYSA-N 5-[4-[[2-(trifluoromethyl)phenyl]methyl]piperazine-1-carbonyl]pyrrolidin-2-one Chemical compound FC(F)(F)C1=CC=CC=C1CN1CCN(C(=O)C2NC(=O)CC2)CC1 UWQPTPXCKMIZQJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RFRUXGCVYWNHJO-OURKGEEVSA-N C(\C=C/C(=O)O)(=O)O.O1CCN(CC1)C(=O)CN1CCN(CC1)C(=O)[C@@H]1CCC(N1)=O Chemical compound C(\C=C/C(=O)O)(=O)O.O1CCN(CC1)C(=O)CN1CCN(CC1)C(=O)[C@@H]1CCC(N1)=O RFRUXGCVYWNHJO-OURKGEEVSA-N 0.000 description 1
- VGIODZUECSTLFY-HEKVCFEKSA-N C(\C=C/C(=O)O)(=O)O.S1CCN(CC1)C(=O)CN1CCN(CC1)C(=O)[C@H]1CCC(N1)=O Chemical compound C(\C=C/C(=O)O)(=O)O.S1CCN(CC1)C(=O)CN1CCN(CC1)C(=O)[C@H]1CCC(N1)=O VGIODZUECSTLFY-HEKVCFEKSA-N 0.000 description 1
- BOZXVPZQVZMURY-WLHGVMLRSA-N C1CNCCNC1.OC(=O)\C=C\C(O)=O Chemical compound C1CNCCNC1.OC(=O)\C=C\C(O)=O BOZXVPZQVZMURY-WLHGVMLRSA-N 0.000 description 1
- BKHGHAJVGVBDBE-ZDUSSCGKSA-N CC1=CC=CC=C1N1CCN(C(=O)[C@H]2NC(=O)CC2)CC1 Chemical compound CC1=CC=CC=C1N1CCN(C(=O)[C@H]2NC(=O)CC2)CC1 BKHGHAJVGVBDBE-ZDUSSCGKSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 101100081581 Chlamydomonas reinhardtii ODA1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102220506674 MKRN2 opposite strand protein_H26N_mutation Human genes 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102220502023 Ubiquitin-like modifier-activating enzyme 1_H25N_mutation Human genes 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QPZJXYPDBUSTMG-UHFFFAOYSA-N benzyl 4-(5-oxopyrrolidine-2-carbonyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)C2NC(=O)CC2)CCN1C(=O)OCC1=CC=CC=C1 QPZJXYPDBUSTMG-UHFFFAOYSA-N 0.000 description 1
- QPZJXYPDBUSTMG-CQSZACIVSA-N benzyl 4-[(2r)-5-oxopyrrolidine-2-carbonyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)[C@@H]2NC(=O)CC2)CCN1C(=O)OCC1=CC=CC=C1 QPZJXYPDBUSTMG-CQSZACIVSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- RKPBUCZXDBLXMV-UHFFFAOYSA-N benzyl n-[4-oxo-4-[4-(5-oxopyrrolidine-2-carbonyl)piperazin-1-yl]butyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCCCC(=O)N(CC1)CCN1C(=O)C1CCC(=O)N1 RKPBUCZXDBLXMV-UHFFFAOYSA-N 0.000 description 1
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- UXXXZMDJQLPQPH-UHFFFAOYSA-N bis(2-methylpropyl) carbonate Chemical compound CC(C)COC(=O)OCC(C)C UXXXZMDJQLPQPH-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- RBISEIMZVBJUQE-UHFFFAOYSA-N ethyl 1-(5-oxopyrrolidine-2-carbonyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)C1NC(=O)CC1 RBISEIMZVBJUQE-UHFFFAOYSA-N 0.000 description 1
- UNNWZHOQBNHIPV-UHFFFAOYSA-N ethyl 4-(5-oxopyrrolidine-2-carbonyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)C1NC(=O)CC1 UNNWZHOQBNHIPV-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FBDNAAHPQWAFQZ-UHFFFAOYSA-N methyl 4-[2-[4-(5-oxopyrrolidine-2-carbonyl)piperazin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCN1CCN(C(=O)C2NC(=O)CC2)CC1 FBDNAAHPQWAFQZ-UHFFFAOYSA-N 0.000 description 1
- UPPPILNTMCMVRO-UHFFFAOYSA-N methyl 4-[3-[4-(5-oxopyrrolidine-2-carbonyl)piperazin-1-yl]propoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCCN1CCN(C(=O)C2NC(=O)CC2)CC1 UPPPILNTMCMVRO-UHFFFAOYSA-N 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 1
- 229960003389 pramiracetam Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、医薬品として有用なピログルタミド誘導体及
びその塩類に関する。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to pyroglutamide derivatives and salts thereof useful as pharmaceuticals.
更に詳しくは、本発明は、次の一般式CI)で表わされ
るピログルタミド誘導体に関する。More specifically, the present invention relates to pyroglutamide derivatives represented by the following general formula CI).
ここにAは、□置換基を有するか又は有しない環状アミ
ノ基を表わす。そしてこの環状アミノ基は、環の中に窒
素原子以外にヘテロ原子として更に窒素原子を含んでい
てもよい。またこの置換基としては、次に掲げる■〜◎
のものを挙げることができる。Here, A represents a cyclic amino group with or without a □ substituent. The cyclic amino group may further contain a nitrogen atom as a hetero atom in addition to the nitrogen atom in the ring. In addition, as this substituent, the following ■~◎
I can list the following.
■アルキル、■ジアリールアルキル、■アラルキル、■
アリール、■ヒドロキシアルキル、■ヒドロキシ、■ア
ルカノイル、■アラルキルカルボニル、■アラルキルオ
キシカルボニル、[相]アラルケニルカルボニル、■ア
リールカルボニル(アロイル)、[相]複素環カルボニ
ル、0アルコキシカルボニル、■アミノアルキル、[相
]アミノアルキルカルボニル、■アミノカルボニル(カ
ルバモイル)、■カルバモイルアルキル、@カルバモイ
ルアルキルカルボニル、0オキソ、[相]複素環、■了
り−ルオキシアルキル、◎アルカノイルアミノ。■Alkyl, ■diarylalkyl, ■aralkyl, ■
Aryl, ■Hydroxyalkyl, ■Hydroxy, ■Alkanoyl, ■Aralkylcarbonyl, ■Aralkyloxycarbonyl, [Phase] Aralkenylcarbonyl, ■Arylcarbonyl (aroyl), [Phase] Heterocyclic carbonyl, 0 alkoxycarbonyl, ■Aminoalkyl , [Phase] aminoalkylcarbonyl, ■aminocarbonyl (carbamoyl), ■carbamoylalkyl, @carbamoylalkylcarbonyl, 0oxo, [phase]heterocycle, ■Ori-ruoxyalkyl, ◎alkanoylamino.
(従来の技術)
人口の高齢化に伴って、痴呆が老人医療のうちに大きな
ウェイトを占めるに至っているが、いまだその治療法は
確立されていない。脳代謝賦活剤、脳血流改善剤、トラ
ンキライザー、コリン作動薬等の薬物療法が試みられつ
つあるが、効果は不定で満足モきる医薬品はない。(Prior Art) As the population ages, dementia has come to occupy a large portion of geriatric medical care, but no treatment method has yet been established. Drug treatments such as brain metabolism activators, cerebral blood flow improvers, tranquilizers, and cholinergic agonists are being tried, but the effects are uncertain and no drug has been satisfactory.
最近、向知性薬(Nootropic )として、アニ
ラセタムやプラミラセタム等いくつかの化合物が開発さ
れつつある。また、特開昭52−125166号公報や
特開昭51−115472号公報には、TRH(Thy
rotropinreleasing hormone
)化合物が開示されている。Recently, several compounds such as aniracetam and pramiracetam are being developed as nootropics. In addition, JP-A-52-125166 and JP-A-51-115472 also include TRH (Thy
rotopinreleasinghormone
) compounds are disclosed.
(発明が解決しようとする問題点)
本発明者らは、上記のこれまでの痴呆治療を目的とする
医薬品開発の遅れの現状に鑑み、全く新しい視点から優
れた向知性作用を有する物質の創製を試みた。本発明の
目的は従って、これまでにないタイプの向知性薬を提供
することにあった。(Problems to be Solved by the Invention) In view of the above-mentioned current state of delays in the development of pharmaceuticals aimed at treating dementia, the present inventors aimed to create a substance with excellent nootropic effects from a completely new perspective. I tried. The object of the present invention was therefore to provide a nootropic of a type hitherto unknown.
(問題点を解決するための手段)
本発明者らは永年にわたって、新規化合物を合成しそれ
らについてその向知性作用を検討していたが、幸運なこ
とに上記一般式(1)で表わされる化合物が哺乳動物に
対して優れた向知性作用を有しかつ毒性も極めて低いこ
とを見いだし、本発明を完成するに至ったものである。(Means for Solving the Problems) The present inventors have been synthesizing new compounds and studying their nootropic effects for many years, and fortunately, the compound represented by the above general formula (1) The present invention was completed based on the discovery that it has an excellent nootropic effect on mammals and has extremely low toxicity.
本発明は一般式(1)で表わされるものであるが、特開
昭51−8266号公報にはN−ピペリジノピログルタ
ミド及びN−ピロリジノピログルタミドが、抗潰瘍剤の
製造中間体として開示されている。またこれらの化合物
は、特公昭49−14462号公報にも原料として開示
されている。従って、一般式(1)で表わされる化合′
物のうち、Aが無置換のピロリジノ又はピペリジノであ
る化合物については、本発明に関する薬理作用を示唆す
る記載はないが新規化合物であるとはいえないので、本
発明はこれら化合物を含まないものである。The present invention is expressed by the general formula (1), and JP-A-51-8266 discloses that N-piperidinopyroglutamide and N-pyrrolidinopyroglutamide are used as intermediates in the production of anti-ulcer agents. It is disclosed as a body. These compounds are also disclosed as raw materials in Japanese Patent Publication No. 49-14462. Therefore, the compound represented by general formula (1)'
Among the compounds, compounds in which A is unsubstituted pyrrolidino or piperidino are not described as having pharmacological effects related to the present invention, but cannot be said to be new compounds. Therefore, the present invention does not include these compounds. be.
一般式(1)におけるAで表わされる環状アミノ基とし
ては、例えば、員数4〜10の環状アミノ基を挙げるこ
とができる。Examples of the cyclic amino group represented by A in general formula (1) include cyclic amino groups having 4 to 10 members.
このようなアミノ基の具体例としては、例えば、アゼチ
ジン、ピロリジノ、ピペリジノ、アゼピノ、アゾジノ、
ピペラジノ、ホモピペラジノ、テトラヒドロイソキノリ
ノ等を挙げることができる。Specific examples of such amino groups include azetidine, pyrrolidino, piperidino, azepino, azodino,
Examples include piperazino, homopiperazino, and tetrahydroisoquinolino.
これらの環状アミノ基は、任意の位置に置換基を有する
ことができる。このような置換基としては前記した■〜
■のものを挙げることができる。These cyclic amino groups can have a substituent at any position. Examples of such substituents include the above-mentioned ■~
I can list the following.
ここに、上記■〜Oがアリールを含む場合には、そのア
リールが、アルキル、アルコキシ、アラルキルオキシ、
アルカノイル、アルコキシカルボニル、ハロゲン、ハロ
ゲノアルキル、ニトロ又はメチレンジオキシから選択さ
れる1個以上の同−又は異なる置換基によって置換され
ている場合も含むものとする。Here, when the above ■ to O include aryl, the aryl is alkyl, alkoxy, aralkyloxy,
It shall also include cases where it is substituted with one or more of the same or different substituents selected from alkanoyl, alkoxycarbonyl, halogen, halogenoalkyl, nitro or methylenedioxy.
また、上記Φ〜■がアミノ基を含む場合には、そのアミ
ノ基が員数4〜8の環状を形成する場合(この場合には
、この環中に窒素原子以外にヘテロ原子として更に窒素
原子、硫黄原子又は酸素原子を含んでいるか、又は窒素
原子1個のみをヘテロ原子とするものとする)を含むも
のとする。これらの環状アミノ基としては、ピロリジノ
、ピペリジノ、アゼピノ、ピペラジノ、モルホリノ、チ
オモルホリノ等を挙げることができる。これらのアミノ
基は同−又は異なる1個以上のアルキル、アラルキル、
アラルキルオキシカルボニル、若しくはカルバモイルに
よって置換されている場合も含むものとする。In addition, when the above Φ to ■ contains an amino group, the amino group forms a ring having 4 to 8 members (in this case, in addition to the nitrogen atom in this ring, a nitrogen atom is added as a hetero atom, It shall contain a sulfur atom or an oxygen atom, or only one nitrogen atom shall be a heteroatom). Examples of these cyclic amino groups include pyrrolidino, piperidino, azepino, piperazino, morpholino, thiomorpholino, and the like. These amino groups are the same or different one or more alkyl, aralkyl,
It shall also include cases where it is substituted with aralkyloxycarbonyl or carbamoyl.
これらの置換基を更に具体的に記載すれば、以下のもの
を挙げることができる。More specific descriptions of these substituents include the following.
即ち、アルキルとしては、直鎮状又は分枝状の炭素数1
〜4の低級アルキルが好ましく、例えば、メチル、エチ
ル、n−プロピル、イソプロピル、n−ブチル、イソブ
チル、5ec−ブチル、ter t−ブチル等を挙げる
ことができる。That is, as alkyl, straight or branched carbon number 1
-4 lower alkyl is preferred, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 5ec-butyl, tert-butyl and the like.
ジアリールアルキルとしては、アルキルの炭素数が1〜
4のものが好ましく、例えば、ジフェニルメチル、ジフ
ェニルエチル、ジフェニルプロピル、ジフェニルブチル
等を挙げることができる。As diarylalkyl, the number of carbon atoms in the alkyl is 1 to
4 is preferred, and examples thereof include diphenylmethyl, diphenylethyl, diphenylpropyl, diphenylbutyl and the like.
アラルキルとしては、炭素数が7〜12のものが好まし
く、例えば、ベンジル、フェネチル、フェニルプロピル
、ナフチルメチル、ナフチルエチル等を挙げることがで
きる。The aralkyl preferably has 7 to 12 carbon atoms, such as benzyl, phenethyl, phenylpropyl, naphthylmethyl, naphthylethyl, and the like.
アリールとしては、例えば、フェニル、α−ナフチル、
β−ナフチル、アントリル、ビフェニル等を挙げること
ができる。Examples of aryl include phenyl, α-naphthyl,
Examples include β-naphthyl, anthryl, biphenyl, and the like.
ヒドロキシアルキルとしては、炭素数2〜4のものが好
ましく、任意の位置にヒドロキシ基を有することができ
る。例えば、2−ヒドロキシエチル、3−ヒドロキシプ
ロピル、4−ヒドロキシブチル、2−ヒドロキシプロピ
ル等を挙げることができる。The hydroxyalkyl preferably has 2 to 4 carbon atoms, and can have a hydroxy group at any position. For example, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 2-hydroxypropyl, etc. can be mentioned.
アルカノイルとして1よ、炭素数1〜7のものが好まし
く、例えば、ホルミル、アセチル、プロピオニル、ブチ
リル、イソブチリル、バレリル、イソバレリル、ピバロ
イル、ヘキサノイル、ヘプタノイル等を挙げることがで
きる。The alkanoyl preferably has 1 to 7 carbon atoms, such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl and the like.
アラルキルカルボニルにおけるアラルキル、及び、アラ
ルキルオキシカルボニルにおけるアラルキルとしては、
前記と同じものを挙げることができる。As aralkyl in aralkylcarbonyl and aralkyl in aralkyloxycarbonyl,
The same ones as mentioned above can be mentioned.
アラルケニルカルボニルとしては、炭素数8〜10のも
のが好ましく、例えば、シンナモイル等を挙げることが
できる。The aralkenyl carbonyl preferably has 8 to 10 carbon atoms, such as cinnamoyl.
了り−ルオルボニルにおける了り−ルとしては、前記と
同じものを挙げることができる。As the ori-ru in orbonyl, the same ones as mentioned above can be mentioned.
複素環カルボニルにおける複素環としては、ペテロ原子
として窒素原子、酸素原子又は硫黄原子を1個以上含む
員数4〜8のものが好ましく、例えば、2−ピリジル、
3−ピリジル、4−ピリジル、2−チェニル、3−チェ
ニル、2−フリール、3−フリール、モルホリノ、チオ
モルホリノ等を挙げることができる。The heterocycle in carbonyl heterocycle is preferably one having 4 to 8 members and containing one or more nitrogen atom, oxygen atom or sulfur atom as a petro atom, such as 2-pyridyl,
Examples include 3-pyridyl, 4-pyridyl, 2-chenyl, 3-chenyl, 2-furyl, 3-furyl, morpholino, thiomorpholino, and the like.
アルコキシカルボニルにおけるアルコキシとしては、直
鎖状又は分枝状の炭素数1〜5のものが好ましく、例え
ば、メトキシ、エトキシ、n−プロポキシ、イソプロポ
キシ、n−ブトキシ、イソブトキシ、5ec−ブトキシ
、ter t−ブトキシ、n−ペンチルオキシ、イソペ
ンチルオキシ等を挙げることができる。The alkoxy in alkoxycarbonyl is preferably a linear or branched one having 1 to 5 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, 5ec-butoxy, tert -butoxy, n-pentyloxy, isopentyloxy and the like.
アミノアルキルにおけるアルキル、アミノアルキルカル
ボニルにおけるアルキル、カルバモイルアルキルにおけ
るアルキル、及び、カルバモイルアルキルカルボニルに
おけるアルキルとしては、炭素数1〜3のものが好まし
い。The alkyl in aminoalkyl, the alkyl in aminoalkylcarbonyl, the alkyl in carbamoylalkyl, and the alkyl in carbamoylalkylcarbonyl preferably have 1 to 3 carbon atoms.
複素環としては、複素環カルボニルの説明で述べたもの
と同じものを挙げることができる。As the heterocycle, the same ones as mentioned in the explanation of heterocycle carbonyl can be mentioned.
ハロゲンとしては、例えば、塩素、臭素、フッ素、ヨウ
素等を挙げることができる。Examples of the halogen include chlorine, bromine, fluorine, and iodine.
アラルキルオキシにおけるアラルキルとしては、前記と
同じものを挙げることができる。As the aralkyl in aralkyloxy, the same ones as mentioned above can be mentioned.
ハロゲノアルキルとしては、例えば、トリフルオロメチ
ル等を挙げることができる。Examples of halogenoalkyl include trifluoromethyl.
■ ヒA の l゛
本発明化合物は、例えば、以下に示す方法で製造するこ
とができる。■ The compound of the present invention can be produced, for example, by the method shown below.
(以下次頁)
jl
(n) (I)l1
:
(n[) (1)立法
:
(IV) (Ia)
(Rはへの置換基を表わし、Xはハロゲンを表わす。)
、m汰:
(IV) (Ib)(C
o R’はAの置換基中のアシル残基を表わす、)旦:
(IV)
(Ic)
3を表わし、Xはハロゲンを表わす、)以下に個々の製
造法について詳述する。(Next page below) jl (n) (I)l1
: (n[) (1) Legislation: (IV) (Ia)
(R represents a substituent and X represents a halogen.)
, m: (IV) (Ib) (C
o R' represents an acyl residue in the substituent of A, ) represents (IV) (Ic) 3, and X represents a halogen.) The individual production methods are detailed below.
A法:
化合物(II)に種々のアミンを反応させて(1)を製
造する。このアミド化反応は、それ自体公知の方法で行
うことができる0例えば、(It)に対して当モル以上
の、好ましくは1.0〜1.3モルのアミンを用い、通
常的50〜160℃、好ましくは、約90〜120℃の
温度で行うことができる。特に便宜的には、使用する溶
媒の沸点で行うことができる。Method A: Compound (1) is produced by reacting various amines with compound (II). This amidation reaction can be carried out by a method known per se. For example, the amidation reaction can be carried out by a method known per se. C, preferably at a temperature of about 90 to 120C. Particularly expediently, it can be carried out at the boiling point of the solvent used.
かかる溶媒としては不活性なものであればいかなるもの
であってもよく、例えばメタノール、エタノール、イソ
プロパツールのようなアルコール系溶媒、クロロホルム
、四塩化炭素のようなハロゲン化炭化水素系溶媒、ベン
ゼン、トルエン、キシレンのような芳香族炭化水素系溶
媒、テトラヒドロフラン、ジオキサンのようなエーテル
類系溶媒、又は、N、N−ジメチルホルムアミドのよう
な非プロトン性極性溶媒を用いることができ、更に無溶
媒であってもよい。Any inert solvent may be used as such a solvent, such as alcohol solvents such as methanol, ethanol, and isopropanol, halogenated hydrocarbon solvents such as chloroform and carbon tetrachloride, and benzene. , aromatic hydrocarbon solvents such as toluene and xylene, ether solvents such as tetrahydrofuran and dioxane, or aprotic polar solvents such as N,N-dimethylformamide. It may be.
B法:
化合物(I[[)に種々のアミンを反応させて(1)を
製造する。このアミド化反応は、それ自体公知の方法で
行うことができる6例えば、(m)と種々のアミンをジ
シクロへキシルカルボジイミド(DCC)やジフェニル
ホスホリルアジド(DDPA)などで直接縮合する方法
、又は(III)の反応性誘導体、例えば、酸無水物、
イミダゾリド或いは混合酸無水物(メチル炭酸との無水
物、エチル炭酸との無水物、イソブチル炭酸との無水物
など)等を適宜反応させる方法、活性エステル法などを
用いることができる。これらのうち、縮合剤、例えば、
nccを用いる場合には反応は適当な溶媒(例えば、塩
化メチレン、クロロホルムのようなハロゲン化炭化水素
類、テトラヒドロフラン、ジオキサンのようなエーテル
系溶媒、アセトニトリル、N、N−ジメチルホルムアミ
ドなど)中で、約−30℃〜約180℃で行われる。ア
ミン1モルに対して等モルないし少し過剰の化合物(I
II)及びDCCを用いるのが良い。Method B: Compound (1) is produced by reacting compound (I[[) with various amines. This amidation reaction can be carried out by a method known per se6, for example, by directly condensing (m) with various amines using dicyclohexylcarbodiimide (DCC) or diphenylphosphoryl azide (DDPA), or ( III) reactive derivatives such as acid anhydrides,
A method of reacting an imidazolide or a mixed acid anhydride (such as an anhydride with methyl carbonate, an anhydride with ethyl carbonate, an anhydride with isobutyl carbonate, etc.), an active ester method, etc. can be used. Among these, condensing agents, e.g.
When using ncc, the reaction is carried out in a suitable solvent (e.g., methylene chloride, halogenated hydrocarbons such as chloroform, ethereal solvents such as tetrahydrofuran, dioxane, acetonitrile, N,N-dimethylformamide, etc.). It is carried out at a temperature of about -30°C to about 180°C. Equimolar to slightly excess amount of compound (I) per mole of amine
II) and DCC are preferably used.
一般式(1)でAがへテロ原子として更に窒素原子を有
する環状アミノ基であってその窒素が置換されている場
合の化合物については、上記製造方法により製造された
化合物をアルキル化、アシル化又はアミノ化等をするこ
とによっても、製造することができる。即ちC〜E法で
製造することができる。For compounds in general formula (1) where A is a cyclic amino group having a nitrogen atom as a heteroatom and the nitrogen is substituted, the compound produced by the above production method may be alkylated or acylated. Alternatively, it can be produced by amination, etc. That is, it can be manufactured by methods C to E.
C法:
A法又はB法で得られた(IV)をアルキル化して(I
a)を得ることができる。このアルキル化反応は、それ
自体公知の方法で行うことができる。Method C: Alkylating (IV) obtained by method A or method B to form (I
a) can be obtained. This alkylation reaction can be carried out by a method known per se.
アルキル化剤としては、通常のアルキル化反応に用いら
れるものを使用することができ、例えば、対応するアル
キルハライド(クロリド、プロミド、ヨーダイトなど)
、硫酸エステル、スルホン酸エステル等を挙げることが
できる0例えば、アルキルハライドを用いる場合、反応
は適当な溶媒(例えば、メタノール、エタノール等のよ
うなアルコール類、テトラヒドロフラン、ジオキサン等
のようなエーテル類、塩化メチレン、クロロホルム等の
ようなハロゲン化炭化水素類、ベンゼン、トルエン等の
ような芳香族炭化水素類、アセトニトリル、N、N−ジ
メチルホルムアミド等のような非プロトン性極性溶媒、
又ははこれらの混合物など)中で、塩基(例えば、炭酸
水素ナトリウム、炭酸カリウム、ピリジン、トリアルキ
ルアミンなど)の存在下に、室温ないし反応溶媒の沸点
で行うのが良い。As the alkylating agent, those used in normal alkylation reactions can be used, such as the corresponding alkyl halide (chloride, bromide, iodite, etc.)
For example, when using an alkyl halide, the reaction can be carried out using a suitable solvent (e.g., alcohols such as methanol, ethanol, etc., ethers such as tetrahydrofuran, dioxane, etc.). halogenated hydrocarbons such as methylene chloride, chloroform etc., aromatic hydrocarbons such as benzene, toluene etc., aprotic polar solvents such as acetonitrile, N,N-dimethylformamide etc.
or a mixture thereof) in the presence of a base (eg, sodium bicarbonate, potassium carbonate, pyridine, trialkylamine, etc.) at room temperature to the boiling point of the reaction solvent.
この場合には(IV)に対して当量又はそれ以上のアル
キルハライドを使用するのが良い、そして、反応促進、
収率向上のために、触媒量(0,01〜0.1モル当量
程度)のヨウ化ナトリウム又はヨウ化カリウムを加える
ことができる。In this case, it is preferable to use an equivalent or more amount of alkyl halide to (IV), and to promote the reaction,
In order to improve the yield, a catalytic amount (about 0.01 to 0.1 molar equivalent) of sodium iodide or potassium iodide can be added.
D法:
A法又はB法で得られる(IV)をアシル化すれば〔!
b〕を得ることができる。このアシル化反応は、B法と
実質的に同様の方法により行うことができるほか、酸ハ
ライドを(IV)と反応させることによっても製造する
ことができる。Method D: If (IV) obtained by method A or method B is acylated, [!
b] can be obtained. This acylation reaction can be performed by a method substantially similar to method B, and can also be produced by reacting an acid halide with (IV).
酸ハライドを用いる場合には、反応は通常、溶媒(例え
ば、テトラヒドロフラン、ジオキサン等のようなエーテ
ル類、塩化メチレン、クロロホルム等のようなハロゲン
化炭化水素類、ベンゼン、トルエン等のような芳沓族炭
化水素類、アセトニトリル、N。When using an acid halide, the reaction is usually carried out in a solvent such as ethers such as tetrahydrofuran, dioxane, etc., halogenated hydrocarbons such as methylene chloride, chloroform, etc., aromatic solvents such as benzene, toluene, etc. Hydrocarbons, acetonitrile, N.
N−ジメチルホルムアミド、等のような非プロトン性極
性溶媒、水又はこれらの混合物など)中で、塩基(例え
ば、炭酸水素ナトリウム、炭酸カリウム、水酸化ナトリ
ウム、水酸化カリウム、ピリジン、トリアルキルアミン
など)の存在下に、反応温度約−10’C〜約100℃
で行うのが良い。bases (e.g., sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, pyridine, trialkylamines, etc.) in aprotic polar solvents such as N-dimethylformamide, etc., water or mixtures thereof. ) at a reaction temperature of about -10'C to about 100'C.
It is better to do it with
この場合には酸ハライドの使用量は(mV)に対して当
量又はそれ以上であるのが良い。In this case, the amount of acid halide used is preferably equivalent to (mV) or more.
E法:
A法又はB法で得られた(IV)をアシル化した後にア
ミンを反応させて(Ic)を製造することができる。こ
れらの反応は、実質的にはD法又はE法と同様にして行
うことができる。Method E: (Ic) can be produced by acylating (IV) obtained by method A or method B and then reacting with an amine. These reactions can be carried out substantially in the same manner as Method D or Method E.
上記の製造法においてピペラジンのようなジアミンを反
応させる場合には、一方のアミンを公知の方法によって
保護して(n)又は(III)と反応させ、ついで保護
基を脱離させて(1)を得る。When reacting a diamine such as piperazine in the above production method, one of the amines is protected by a known method and reacted with (n) or (III), and then the protecting group is removed to form (1). get.
上記の各製造方法の原料として用いられる(II)及び
(DI)は市販されており容易に入手することができる
ものである。また、同様にアミン類は市販されいるか又
は公知の方法により製造することができるものである。(II) and (DI) used as raw materials for each of the above production methods are commercially available and can be easily obtained. Similarly, amines are commercially available or can be produced by known methods.
上記の各方法によって得られた化合物(1)は、それ自
体公知の方法によって遊離塩基の形で単離することがで
きる0例えば、濃縮、液性変換、転溶、溶媒抽出、結晶
化、再結晶、分溜、クロマトグラフィー等により単離精
製することができるのである。Compound (1) obtained by each of the above methods can be isolated in the form of a free base by methods known per se. For example, concentration, liquid conversion, dissolution, solvent extraction, crystallization, reconstitution, etc. It can be isolated and purified by crystallization, fractional distillation, chromatography, etc.
また、酸付加塩の形で単離することもできる。このよう
な酸付加塩としては、生理学的に許容されるものであれ
ば良く、例えば、塩酸塩、臭化水素酸塩、硫酸塩、リン
酸塩等のような無機酸塩、酢酸塩、マレイン酸塩、フマ
ール酸塩、コハク酸塩、酒石酸塩、クエン酸塩、リンゴ
酸塩等のような有機酸塩を挙げることができる。It can also be isolated in the form of acid addition salts. Such acid addition salts may be physiologically acceptable, such as inorganic acid salts such as hydrochlorides, hydrobromides, sulfates, phosphates, acetates, maleic acid salts, etc. Mention may be made of organic acid salts such as acid salts, fumarates, succinates, tartrates, citrates, malates, etc.
本発明化合物は一般式CI)で表わされるが、その中に
不斉炭素を有することが明白である(下記の*印)。The compound of the present invention is represented by the general formula CI), and it is clear that it has an asymmetric carbon in it (marked with * below).
本発明化合物は従って、D体とL体の光学活性体が存在
するが、各光学異性体及びこれらの混合物のいずれも当
然に本発明の範囲に含まれるものである。Therefore, the compound of the present invention exists in D-form and L-form optically active forms, and each optical isomer and mixtures thereof are naturally included within the scope of the present invention.
これらの異性体は所望により個別に製造することができ
る。These isomers can be prepared individually if desired.
例えば、原料化合物(n)又は(I[[)として光学活
性体(D体又はL体)を用いることにより、対応する(
1)の光学異性体(D体又はL体)を得ることができる
。また、製造したCI)がD体とL体の混合物である場
合には、これらを通常の光学分割の方法によってそれぞ
れの異性体に分離精製することができる。For example, by using an optically active form (D form or L form) as the starting compound (n) or (I[[), the corresponding (
The optical isomer (D-form or L-form) of 1) can be obtained. Further, when the produced CI) is a mixture of D-form and L-form, these can be separated and purified into each isomer by a conventional optical resolution method.
このようにして得られる光学活性な(I)のうちでは、
一般的にD体の方が対応するL体よりも好ましい生理活
性を有することが判っている。Among the optically active (I) obtained in this way,
It is generally known that the D-form has more favorable physiological activity than the corresponding L-form.
以下に本発明化合物の有用性を示す薬理試験の結果を詳
述する。The results of pharmacological tests demonstrating the usefulness of the compounds of the present invention are detailed below.
1、スコポラミン健忘症に対する改善効果試験法:受動
的回避学習(PAR)獲得(獲得試行)後、ラットにス
コポラミン0.5mg/kgと、被験薬を同時に腹腔内
に投与し、1時間後に再び受動的回避学習反応(再生試
行)を行った。そのときの反応陽性率(陽性動物数/使
用動物数)を表1に示した。1. Testing method for the improvement effect on scopolamine amnesia: After passive avoidance learning (PAR) acquisition (acquisition trial), 0.5 mg/kg of scopolamine and the test drug were simultaneously administered intraperitoneally to the rats, and 1 hour later, the rats were given passive avoidance learning (PAR) again. A target avoidance learning response (reproduction trial) was performed. The positive reaction rate (number of positive animals/number of animals used) at that time is shown in Table 1.
上記試験において被験薬を経口投与した場合には、再生
試行は薬物投与2時間後に行った。When the test drug was orally administered in the above test, the regeneration trial was performed 2 hours after drug administration.
アニラセタム、実施例番号3及び72の化合物を腹腔内
及び経口投与した時、有意の改善効果を示す最小有効量
を表2の(1)に示した。When aniracetam and the compounds of Example Nos. 3 and 72 were administered intraperitoneally and orally, the minimum effective doses showing significant improvement effects are shown in Table 2 (1).
表1
* : p <0.05. * * : p <0
.01本発明化合物の顕著な効果が明白である。Table 1 *: p <0.05. * * : p < 0
.. 01 The remarkable effects of the compounds of the present invention are obvious.
2、電気ショック健忘症に対する改善効果スコポラミン
健忘症と同様の方法を用いた。2. Improving effect on electric shock amnesia The same method as for scopolamine amnesia was used.
獲得試行後ラットに電撃ショックを与え、痙来が治って
後、被験薬を腹腔内投与及び経口投与し、それぞれ1及
び3時間後に再生試行を行い、反応陽性率を測定し、有
意の改善効果を示す最少有効量を表2の(2)に示した
。After the acquisition trial, rats were given an electric shock, and after the convulsions had subsided, the test drug was administered intraperitoneally and orally. Reproduction trials were performed 1 and 3 hours later, respectively, and the positive response rate was measured, indicating a significant improvement effect. The minimum effective amount showing this is shown in (2) of Table 2.
3、過剰co2健忘症に対する改善効果被験薬を腹腔内
投与又は経口投与した後、それぞれ30分及び60分後
に、ラットを、C02ガスを充満させたチャンバーの中
に12秒間置き、その3分後に2コンパートメントシヤ
トルボツクス内に移し、ブザーを条件刺激とする能動的
回避学習及び逃避学習を行わせ、6試行目の学習獲得試
験の陽性率(陽性動物数/使用動物数)を測定し、有意
の改善効果を示す最少有効量を表2の(3)に示した。3. Improving effect on excess CO2 amnesia 30 and 60 minutes after intraperitoneal or oral administration of the test drug, respectively, the rats were placed in a chamber filled with CO2 gas for 12 seconds, and 3 minutes later. The animals were transferred to a two-compartment shuttle box and subjected to active avoidance learning and escape learning using a buzzer as a conditioned stimulus, and the positive rate (number of positive animals/number of animals used) of the learning acquisition test on the sixth trial was measured. The minimum effective dose showing the improvement effect is shown in (3) of Table 2.
表2中の最少有効量は、いずれもx2検定においてp<
0.05で有意の改善効果を示す有効量(mg/kg)
で表した。The minimum effective doses in Table 2 are all p<
Effective amount (mg/kg) showing significant improvement effect at 0.05
It was expressed as
表2
(1)スコポラミン健忘症に対する改善効果(2)電気
ショック健忘症に対する改善効果(3)過剰co2健忘
症に対する改善効果本発明化合物の有用なる効果が明白
である。Table 2 (1) Improving effect on scopolamine amnesia (2) Improving effect on electric shock amnesia (3) Improving effect on excess CO2 amnesia The useful effects of the compounds of the present invention are obvious.
4、急性毒性
雄性マウスに実施例番号3.72の本発明化合物を静脈
内投与及び経口投与後、7日間その毒性症状を観察した
。4. Acute Toxicity After the compound of the present invention of Example No. 3.72 was administered intravenously and orally to male mice, toxicity symptoms were observed for 7 days.
1000 mg/kgの静脈内投与で、いずれの化合物
についても死亡例はなくかつ毒性症状は殆ど認められな
かった。When administered intravenously at 1000 mg/kg, there were no deaths and almost no toxic symptoms were observed for any of the compounds.
また経口投与の場合には、5000 mg/kgで、い
ずれの化合物についても死亡例はなくかつ毒性症状は認
められなかった。In the case of oral administration, there were no deaths and no toxic symptoms were observed for any of the compounds at 5000 mg/kg.
本発明化合物の安全性が明らかである。The safety of the compounds of the present invention is clear.
本発明化合物を医薬品として投与する場合、本発明化合
物はそのまま又は医薬的に許容される無毒性かつ不活性
の担体中に、例えば0.1%〜99.5%、好ましくは
0.5%〜90%含有する医薬組成物として、人を含む
動物に投与するのが良い。When the compound of the present invention is administered as a pharmaceutical, the compound of the present invention may be administered as is or in a pharmaceutically acceptable non-toxic and inert carrier, for example, from 0.1% to 99.5%, preferably from 0.5% to It is preferable to administer it to animals, including humans, as a pharmaceutical composition containing 90%.
担体としては、固形、半固形又は液状の希釈剤、充填剤
、及びその他の処方用の助剤一種以上が用いられる。医
薬組成物は、投与単位形態で投与することが望ましい。As carriers, one or more solid, semisolid or liquid diluents, fillers and other formulation auxiliaries are used. Preferably, the pharmaceutical composition is administered in dosage unit form.
本発明医薬組成物は、経口投与、組織内投与、局所投与
又は経直腸的に投与することができる。これらの投与方
法に適した剤型、例えば、錠剤、顆粒剤、散剤、カプセ
ル剤、注射剤、坐剤等、で投与されるのはもちろんであ
る0例えば、経口投与が特に好ましい。The pharmaceutical composition of the present invention can be administered orally, interstitially, locally, or rectally. It goes without saying that the drug may be administered in a dosage form suitable for these administration methods, such as tablets, granules, powders, capsules, injections, suppositories, etc. For example, oral administration is particularly preferred.
向知性薬としての用量は、年齢、体重等の患者の状態、
投与経路、病気の性質と程度等を考慮した上で調整する
ことが望ましいが、通常は、成人に対して本発明の有効
成分量として、1日当たり、1mg〜5gの範囲が、好
ましくは150mg〜3gの範囲が一般的である。場合
によっては、これ以下でも足りるしまた逆にこれ以上の
用量を必要とすることもある。The dosage as a nootropic depends on the patient's condition such as age and weight,
Although it is desirable to make adjustments taking into consideration the route of administration, the nature and severity of the disease, etc., the amount of the active ingredient of the present invention for adults is usually in the range of 1 mg to 5 g, preferably 150 mg to 5 g per day. A range of 3g is common. In some cases, a lower dose than this may be sufficient, and in other cases, a higher dose may be required.
また1日数回に分割して投与することもできる。It can also be administered in divided doses several times a day.
(以下次頁)
(実施例)
以下に本発明化合物の製造に関する実施例を掲げて本発
明を更に詳しく説明する。(See next page) (Example) The present invention will be described in more detail below with reference to Examples regarding the production of the compounds of the present invention.
実施例1 (A法)
4−ベンジル−N−(2−ピロリドン−5−カルボニル
)ピペリジン
ピログルタミン酸メチル4.3g 、 4−ベンジルピ
ペリジン7.9gをトルエン20m lに熔解し、かき
まぜながら24時間加熱還流する。反応溶液をシリカゲ
ルカラムクロマトグラフィー処理し、生成物7.2gを
得る。これをジエチルエーテルから再結晶すると、融点
160〜161℃の目的化合物6.5gが得られた。Example 1 (Method A) 4.3 g of methyl 4-benzyl-N-(2-pyrrolidone-5-carbonyl)piperidine pyroglutamate and 7.9 g of 4-benzylpiperidine were dissolved in 20 ml of toluene, and heated with stirring for 24 hours. Reflux. The reaction solution is subjected to silica gel column chromatography to obtain 7.2 g of product. This was recrystallized from diethyl ether to obtain 6.5 g of the target compound having a melting point of 160-161°C.
元素分析値(CI? H22N 202として)計算値
(%) Cニア1.30 Hニア、74 N :9
.7B実測値(%) Cニア1.50 H:8.17
N :9.71実施例2 (B法)
1−(2−ピロリドン−5−カルボニル)ピペラジンピ
ログルタミン酸112.4g 、 N−カルボベンゾキ
シピペラジン147.7g 、ジシクロへキシルカルボ
ジイミド179.7g 、アセトニトリル6.71をか
きまぜながら6時間加熱還流する0反応混合物から不溶
物を濾過で除き、濾液から溶媒を減圧下に留去する。残
留物をシリカゲルカラムクロマトグラフィー処理し、油
状のN−カルボベンゾキシ−N’ −(2−ピロIJ
l’フン−−カルボニル)ピペラジン190gを得る。Elemental analysis value (CI? H22N 202) Calculated value (%) C near 1.30 H near, 74 N: 9
.. 7B actual value (%) C near 1.50 H: 8.17
N: 9.71 Example 2 (Method B) 1-(2-pyrrolidone-5-carbonyl)piperazinepyroglutamic acid 112.4g, N-carbobenzoxypiperazine 147.7g, dicyclohexylcarbodiimide 179.7g, acetonitrile 6 Insoluble matter was removed by filtration from the reaction mixture, which was heated under reflux for 6 hours while stirring, and the solvent was distilled off from the filtrate under reduced pressure. The residue was treated with silica gel column chromatography to obtain oily N-carbobenzoxy-N'-(2-pyro IJ
190 g of l'fun--carbonyl)piperazine are obtained.
この30gをメタノール450m1に熔解し、5%パラ
ジウム炭素3.0gを用いて室温下かきまぜながら接触
還元する0反応液から触媒を濾過で除き、濾液から溶媒
を減圧下に留去し、生成物20 gを得る。これをメタ
ノール−酢酸エチルの混媒から再結晶すると、融点16
2〜163℃の目的化合物17.5 gが得られた。This 30g was dissolved in 450ml of methanol and catalytically reduced using 3.0g of 5% palladium on carbon while stirring at room temperature.The catalyst was removed from the reaction solution by filtration, and the solvent was distilled off from the filtrate under reduced pressure to produce a product of 20g. get g. When this is recrystallized from a methanol-ethyl acetate mixture, it has a melting point of 16
17.5 g of the target compound was obtained at a temperature of 2-163°C.
元素分析値(Cs HISN302として)計算値(%
) C: 54.81 H: 7.67 N :
21.30実測値(%) C: 54.74 H:
7.73 N : 21.29実施例3 (B法)
4−モルホリノカルボニルメチル−1−(2−ピロリド
ン−5−カルボニル)ピペラジン
ピログルタミン酸1.6g 、 1− (モルホリノカ
ルボニルメチル)ピペラジン2.1g 、 DCC2,
47g −及びアセトニトリル130m1の混合溶液を
かきまぜながら48時間加熱還流する0反応混合物から
不溶物を濾過で除き、濾液から溶媒を減圧下に留去する
。残留物をシリカゲルカラムクロマトグラフィー処理°
し、生成物3.0gを得る。これを酢酸エチル−イソプ
ロパノ−ルーローヘキサンの混合溶媒から再結晶すると
、融点167〜169℃の目的化合物2.6gが得られ
た。Elemental analysis value (as Cs HISN302) Calculated value (%
) C: 54.81 H: 7.67 N:
21.30 Actual value (%) C: 54.74 H:
7.73 N: 21.29 Example 3 (Method B) 4-morpholinocarbonylmethyl-1-(2-pyrrolidone-5-carbonyl)piperazinepyroglutamic acid 1.6g, 1-(morpholinocarbonylmethyl)piperazine 2.1g , DCC2,
A mixed solution of 47 g - and 130 ml of acetonitrile is heated under reflux for 48 hours while stirring. Insoluble materials are removed from the reaction mixture by filtration, and the solvent is distilled off from the filtrate under reduced pressure. Treat the residue with silica gel column chromatography
to obtain 3.0 g of product. This was recrystallized from a mixed solvent of ethyl acetate-isopropanol-rohexane to obtain 2.6 g of the target compound having a melting point of 167-169°C.
元素分析値(C+s H24N 404として)計算値
(%) C: 55.54 H: 7.46 N
: 17.27実測値(%) C: 55.31 H
: 7.49 N : 17.14実施例4 (C法
)
4−モルホリノカルボニルメチル−1−(2−ピロリド
ン−5−カルボニル)ピペラジン
1−<2−ピロリドン−5−カルボニル)ピペラジン3
.7g 、4−クロルアセチルモルホリン3.7g 、
無水炭酸カリウム4.4g 、及びN、N−ジメチルホ
ルムアミド20n+1を加え、攪拌しながら70〜75
℃で1時間加熱する0反応混合物から不溶物を濾去し、
濾液から溶媒を減圧下に留去する。残留物をシリカゲル
カラムクロマトグラフィーで精製し、生成物5.7gを
得る。Elemental analysis value (as C+s H24N 404) Calculated value (%) C: 55.54 H: 7.46 N
: 17.27 Actual value (%) C: 55.31 H
: 7.49 N : 17.14 Example 4 (Method C) 4-morpholinocarbonylmethyl-1-(2-pyrrolidone-5-carbonyl)piperazine 1-<2-pyrrolidone-5-carbonyl)piperazine 3
.. 7g, 4-chloroacetylmorpholine 3.7g,
Add 4.4 g of anhydrous potassium carbonate and 20n+1 N,N-dimethylformamide, and bring to a boiling temperature of 70 to 75 g while stirring.
Insoluble material was filtered off from the reaction mixture heated for 1 h at 0°C;
The solvent is distilled off from the filtrate under reduced pressure. The residue is purified by silica gel column chromatography to obtain 5.7 g of product.
これを、エタノール−酢酸エチル−ジエチルエーテルの
混合溶媒から再結晶すると、融点167〜169℃の目
的化合物4.2gが得られた。This was recrystallized from a mixed solvent of ethanol-ethyl acetate-diethyl ether to obtain 4.2 g of the target compound having a melting point of 167-169°C.
元素分析値(C+s 824 N 404として)計算
値(%’) C: 55.54 H: 7.46
N : 17.2’?実測値(%) C: 55.3
6 H: 7.58 N : 17.23実施例5
(D法)
4−エトキシカルボニル−1−(2−ピロリドン−5−
カルボニル)ピペラジン
1−(2−ピロリドン−5−カルボニル)とペラジン2
.1g 、無水炭酸カリウム2.5g 、及びアセトニ
トリル120m1の混合溶液を氷水で冷やし、攪拌しな
がら壱の中にクロル炭酸エチル1.1gをアセトニトリ
ル10m1に溶かした溶液を滴下する。滴下後、更に室
温で一夜攪拌する0反応混合物から溶媒を減圧下に留去
する。残留物に塩化メチレンを加え、不溶物を濾去する
。濾液から溶媒を減圧下に留去し、油状の生成物2.3
gを得る。これを酢酸エチルから結晶化し再結晶すると
、融点147〜148.5℃の目的化合物2.1gが得
られた。Elemental analysis value (as C+s 824 N 404) Calculated value (%') C: 55.54 H: 7.46
N: 17.2'? Actual value (%) C: 55.3
6 H: 7.58 N: 17.23 Example 5
(Method D) 4-ethoxycarbonyl-1-(2-pyrrolidone-5-
carbonyl) piperazine 1-(2-pyrrolidone-5-carbonyl) and perazine 2
.. A mixed solution of 1 g of ethyl chlorocarbonate, 2.5 g of anhydrous potassium carbonate, and 120 ml of acetonitrile is cooled with ice water, and a solution of 1.1 g of ethyl chlorocarbonate dissolved in 10 ml of acetonitrile is added dropwise into the container while stirring. After the addition, the solvent was distilled off under reduced pressure from the reaction mixture, which was further stirred overnight at room temperature. Methylene chloride is added to the residue, and insoluble matter is filtered off. The solvent was distilled off from the filtrate under reduced pressure to obtain an oily product 2.3.
get g. This was crystallized from ethyl acetate and recrystallized to obtain 2.1 g of the target compound having a melting point of 147-148.5°C.
元素分析値(CI2H19N304として)計算値(%
) C: 53.52 H: 7.11 N :
15.60実測値(%) C: 53.36 H:
7.32 N : 15.60実施例6 (E法)
4−モルホリノアセチル−1−(2−ピロリドン−5−
カルボニル)ピペラジン
N−(2−ピロリドン−5−カルボニル)ピペラジン2
.3g 、塩化メチレン50o+ 1、無水炭酸カリウ
ム2.8gの混合溶液を氷水で冷やし、攪拌しながらそ
の中に塩化アセチル1.3g・を滴下する。滴下後、更
に室温で1時間攪拌する。不溶物を濾過で除き、濾液が
ら溶媒を減圧下に留去し、油状のN−(2−ピロリドン
−5−カルボニル)−N′−クロルアセチルビさラジン
2.3gを得る。これを、N、N−ジメチルホルムアミ
ド15m1に溶解し、モルホリン0.8g 、無水炭酸
カリウム2.2gを加え、攪拌しながら80℃で3時間
加熱する0反応混合物から不溶物を濾過で除き、濾液か
ら溶媒を減圧下に留去する。残留物をシリカゲルカラム
クロマトグラフィーで精製し、生成物2.5gを得る。Elemental analysis value (as CI2H19N304) Calculated value (%
) C: 53.52 H: 7.11 N:
15.60 Actual value (%) C: 53.36 H:
7.32 N: 15.60 Example 6 (Method E) 4-morpholinoacetyl-1-(2-pyrrolidone-5-
carbonyl)piperazine N-(2-pyrrolidone-5-carbonyl)piperazine 2
.. A mixed solution of 3 g of methylene chloride, 50 o+1 of methylene chloride, and 2.8 g of anhydrous potassium carbonate was cooled with ice water, and 1.3 g of acetyl chloride was added dropwise thereto while stirring. After the addition, the mixture was further stirred at room temperature for 1 hour. Insoluble matters were removed by filtration, and the solvent was distilled off from the filtrate under reduced pressure to obtain 2.3 g of oily N-(2-pyrrolidone-5-carbonyl)-N'-chloroacetylbisazine. Dissolve this in 15 ml of N,N-dimethylformamide, add 0.8 g of morpholine and 2.2 g of anhydrous potassium carbonate, and heat at 80°C for 3 hours with stirring. Insoluble materials are removed from the reaction mixture by filtration, and the filtrate is The solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography to obtain 2.5 g of product.
これを、メタノールとエチルエーテルの温媒から再結晶
すると、融点204〜205℃の目的化合物2.1gが
得られた。This was recrystallized from a hot medium of methanol and ethyl ether to obtain 2.1 g of the target compound having a melting point of 204-205°C.
元素分析値(C15H24N404として)計算値(%
) C: 55.54 H: 7.46 N :
17.27実測値(%) C: 55.23 H:
7.87 N : 17.01実施例1〜6に記載し
た方法と同様にして、実施例7以下の化合物を製造した
。Elemental analysis value (as C15H24N404) Calculated value (%
) C: 55.54 H: 7.46 N:
17.27 Actual value (%) C: 55.23 H:
7.87 N: 17.01 The following compounds in Example 7 were produced in the same manner as in Examples 1 to 6.
実施例7
4−フェニル−1−(2−ピロリドン−5−カルボニル
)ピペラジン: 融点201〜202℃
元素分析値(CISH19N302として)計算値(%
’) C: 65.91 H: 7.01 N ?
15.37実測値(%) C: 65.93 H:
7.08 N ? 15.12実施例8
4−ベンズヒドリル−1−(2−ピロリドン−5−カル
ボニル)ピペラジン: 融点147〜148.5℃元素
分析値(C22H25N a O2として)計算値(%
) C: 72.70 H: 6.93 N 71
1.56実測値(%) C: 72.53 H: 7
.06 N : 11.32実施例9
4−(3−クロロフェニル’) −1−(2−ピロリド
ン−5−aカルボニル)ピペラジン:融点185.5〜
186.5℃元素分析値(C1s)1+aCIN302
として)計算値(%’) C:58.54H:5.8
9 N:13.65実測値(%) C: 58.5
1 H: 5.92 N : 13.77実施例10
4−(2−クロロフェニル) −1−(2−ピロリドン
−5−カルボニル)ピペラジン;融点165〜167℃
元素分析値(C+5H1sCIN302として)計算値
(%) C: 5B、54 H: 5.89 N
: 13.65実測値(%) C: 58.41 H
: 6.01 N : 13.60実施例11
4−(4−クロロフェニル)−1−(2−ピロリドン−
5−カルボニル)ピペラジン:融点244]5〜246
.5℃元素分析値(C+5H1sCIN302として)
計算値(%) C: 5B、54 H: 5.89
N : 13.65実測値(%) C: 58.5
7 H: 5.92 N : 13.67実施例12
4−(4−フルオロフェニル) −1−(2−ビロリト
ン−5−カルボニル)ピペラジン:融点212〜213
.5℃元素分析値(C+sH+5FN302として)計
算値(%) C: 61.84 H: 6.23
N : 14.42実測値(%) C: 61.77
H: 6.34 N : 14.38実施例13
4−(2−メチルフェニル) −1−(2−ピロリドン
−5−カルボニル)ピペラジン: 融点212〜213
℃元素分析値(CIBH21N302として)計算値(
%’) C: 66.87 H: 7.37 N
? 14.62実測値(%”) C: 66.70
H: 7.50 N : 14.70実施例14
L−(−)−4−(2−メチルフェニル) −1−(2
−ピロリドン−5−カルボニル)ピペラジン:融点12
2〜123.5℃
元素分析値(C+e H21N s O2として)計算
値(%) C: 66.87 H: 7.37 N
714.62実測値(%) C: 66.79 H
: 7.60 N : 14.55実施例15
1−(2−ピロリドン−5−カルボニル) −4−(3
−)リフルオロメチルフェニル)ピペラジン:融点13
3.5〜134.5℃
元素分析値(C+eHteF3Na 02として)計算
値(%) C: 56.30 H: 5.32 N
: 12.31実測値(%”) C: 56.59
H: 5.41 N : 12.41実施例16
4−(2−メトキシフェニル’) −1−(2−ピロリ
ドン−5−カルボニル)ピペラジン:
融点157〜158℃
元素分析値(CI6H21N303として)計算値(%
’) C: 63.35 H: 6.98 N 7
13.85実測値(%) C: 63.25 H:
7.07 N : 13.87実施例17
4−(4−メトキシフェニル)−1−(2−ピロリドン
−5−カルボニル)ピペラジン:
融点190〜192℃
元素分析値(C+e H21N a O3として)計算
値(%) C: 63.35 H: 6.98 N
: 13.85実測値(%) C: 63.19
H: 7.22 N : 13.76実施例18
4−(4−アセチルフェニル) −1−(2−ピロリド
ン−5−カルボニル)ピペラジン:
融点227.5〜229.0℃
元素分析値(C+tH21N303として)計算値(%
) C: 64.74 H: 6.71 N :
13.32実測値(%) C:64.65H:6.8
4 N:13.30実施例19
4−ベンジル−1−(2−ピロリドン−5−カルボニル
)ピペラジン:融点139.5〜141.5℃元素分析
値(CI8H21N302として)計算値(%) C
: 66.88 H: 7.37 N : 14.6
2実測値(%) C: 66.60 H: 7.56
N 214.60実施例20
4−(2−クロロベンジル) −1−(2−ピロリドン
−5−カルボニル)とペラジン:融点92.5〜93.
5℃元素分析値(CI8H20CIN302として)計
算値(%) C: 59.72 H: 6.26
N : 13.06実測値(%) C: 59.72
H: 6.32 N : 13.17実施例21
4−(4−クロロベンジル) −1−(2−ピロリドン
−5−カルボニル)ピペラジン:融点163〜165℃
元素分析値(CI8H20CIN302として)計算値
(%”) C: 59.72 H: 6.26 N
: 13.06実測値(%) C: 59.44
H: 6.39 N : 12.80実施例22
4−(4−フルオロベンジル) −1−(2−ピロリド
ン−5−カルボニル)とペラジン: 融点142〜14
3℃元素分析値(CI8H20FN302として)計算
値(%) C: 62.94 H: 6.60 N
: 13.76実測値(%) C:62.81H:
6.79 N:13.57実施例23
4−(4−メチルベンジル) −1−(2−ピロリドン
−5−カルボニル)ピペラジン:融点144.5〜14
5.5℃元素分析値(CI? H23N 302として
)計算値(%) C: 67.75 H: 7.69
N : 13.94実測値(%) C: 67
.71 H: 7.88 N : 13.94実施例
24
1−(2−ピロリドン−5−カルボニル)−4−(2−
トリフルオロメチルベンジル)ピペラジン へミツマレ
ート:融点133.5〜135.5℃元素分析値(CI
? H2OF 3 N 302・%C4H404として
)
計算値(%) C: 55.20 H: 5.36
N : 10.16実測値(%) C: 55.0
6 H: 5.38 N : 10.12実施例25
4−(4−メトキシベンジル’) −1−(2−ピロI
J t’ノン−−カルボニル)とペラジン:融点145
〜147℃元素分析値(CI? H23N 303とし
て)計算値(%) C: 64.33 H: 7.3
0 N 713.24実測値(%’) C: 64
.29 H: 7.68 N : 13.21実施例
26
4−(3,4−メチレンジオキシベンジル)−1−(2
−ピロリドン−5−カルボニル)ピペラジン:融点10
9〜111℃
元素分析値(CI? H21N 304として)計算値
(%) C: 61.62 H: 6.39 N
: 12.68実測値(%) C: 61.67 H
: 6.55 N : 12.63実施例27
4−ベンゾイル−1−(2−ピロリドン−5−カルボニ
ル)ピペラジン:融点173〜174℃元素分析値(C
I6H19N303として)計算値(%’) C:
63.77 H: 6.35 N ? 13.94実
測値(%) C: 63.59 H: 6.49
N : 13.98実施例28
L (−)−4−ベンゾイル−1−(2−ピロリドン
−5−カルボニル)ピペラジン: 融点113.5〜1
15.5℃元素分析値(C鳳eH+5Na03として)
計算値(%) C: 63.77 H: 6.35
N : 13.94実測値(%’) C: 63.
70 H: 6.82 N : 13.95実施例2
9
4−(2−メチルベンゾイル)−1−(2−ピロIJ
l’ノン−−カルボニル)ピペラジン:融点206〜2
07℃元素分析値(CI?H2重N30重色303計算
値(%) C: 64.74 H: 6.71 N
: 13.32実測値(%) C: 64.49
H: 6.94 N : 13.09実施例30
4−(3−メチルベンゾイル) −1−(2−ピロリド
ン−5−カルボニル)とペラジン:融点175〜176
.5℃元素分析値(CI7H21N303として)計算
値(%) C: 64.74 H: 6.71 N
: 13.32実測値(%’) C: 64.49
H: 6.94 N : 13.09実施例31
4−(4−メチルベンゾイル) −1−(2−ピロリド
ン−5−カルボニル)ピペラジン:
融点162〜164℃
元素分析値(CI? H21N s O3として)計算
値(%) C: 64.74 H: 6.71 N
: 13.32実測値(%) C: 64.41
H: 6.80 N : 13.24実施例32
4−(2,4−ジメチルベンゾイル) −1−(2−ピ
ロリドン−5−カルボニル)ピペラジン:
融点213〜215℃
元素分析値(CI8H23N303として)計算値(%
’) C: 65.63 H: 7.04 N :
12.76実測値(%) C: 65.57 H:
7.26 N : 12.77実施例33
4−(4−メトキシベンゾイル) −1−(2−ピロリ
ドン−5−カルボニル)ピペラジン:
融点180.5〜182.5℃
元素分析値(CI?H21N304として)計算値(%
)C: 61.61 H: 6.39 N : 12
.68実測値(%) C: 61.70 H: 6.
56 N : 12.72実施例34
1−(2−ピロリドン−5−カルボニル)−4−(3゜
4.5− )リメトキシベンゾイル)ピペラジン:融点
170〜172℃
元素分析値(C+s Hzs N 30 sとして)計
算値(%) C: 58.30 H: 6.44
N : 10.74実測値(%) C: 5B、2
7 H: 6.59 N ? 10.75実施例35
4−(4−ニトロベンゾイル) −1−(2−ピロリド
ン−5−カルボニル)ピペラジン:
融点205.5〜207.5℃
元素分析値(CI6HI8N405として)計算値(%
) C: 55.49 H: 5.24 N :
16.18実測値(%) C: 55.33 H:
5.34 N : 16.23実施例36
4−(4−フルオロベンゾイル) −1−(2−ピロリ
ドン−5−カルボニル)ピペラジン:
融点195.5〜197.5℃(分解)元素分析値(C
I6H18FN303として)計算値(%) C:
60.18 H: 5.68 N : 13.16実
測値(%) C: 60.20 H: 5.71
N : 13.20実施例37
4−(2−クロロベンゾイル) −1−(2−ピロリド
ン−5−カルボニル)ピペラジン:
融点175〜177℃
元素分析値(CIeH+aCIN303として)計算値
(%) C: 57.23 H: 5.40 N
: 12.51実測値(%) C: 57.21 H
: 5.46 N : 12.43実施例38
4−(4−クロロベンゾイル) −1−(2−ピロリド
ン−5−カルボニル)ピペラジン:
融点179〜181℃
元素分析値(C電BHI8CIN3 o3として)計算
値(%) C: 57.23 H: 5.40 N
: 12.51実測値(%) C: 56.94
H: 5.54 N : 12.45実施例39
4−(2,4−ジクロロベンゾイル) −1−(2−ピ
ロリドン−5−カルボニル)ピペラジン:
融点206〜208℃
元素分析値(C16Hl?c12 N 303として)
計算値(%) C: 51.91 H: 4.63
N : 11.35実測値(%) C: 52.0
0 H: 4.63 N : 11.31実施例40
4−フェニルアセチル−1−(2−ピロリドン−5−カ
ルボニル)とペラジン:
融点150.5〜152.0℃
元素分析値(C1?H21N303として)計算値(%
) C: 84.74 H: 6.71 N :
13.32実測値(%”) C: 64.37 H:
6.89 N : 13.28実施例4工
4−(4−メトキシフェニルアセチル) −1−(2−
ピロリドン−5−カルボニル)ピペラジン:融点148
.5〜149.5℃
元素分析値(C1?H21N304として)計算値(%
’) C: 62.59 H: 6.71 N :
12.17実測値(%)C: 62.55 H: 6
.90 N : 12.22実施例42
4−(4−クロロフェニルアセチル) −1−(2−ピ
ロリドン−5−カルボニル)ピペラジン:融点185〜
187℃
元素分析値(CI?H2OClN303として)計算値
(%”) C: 58.37 H: 5.76 N
: 12.01実測値(%) C: 58.50
H: 5.84 N : 12.09実施例43
4−/ チル−1−(2−ピロリドン−5−カルボニル
)ピペラジン:
融点129〜131℃
元素分析値(CIOHI?N3 o2として)計算値(
%) C: 56.85 H: 8.11 N 7
19.89実測値(%) C: 56.85 H:
7.96 N : 19.37実施例44
4−アセチル−1−(2−ピロリドン−5−カルボニル
)ピペラジン:
融点118〜123℃
元素分析値(Co H1?N303
・ 1/6H20として)
計算値(%) C: 54.53 H: 7.21
N : 17.34実測値(%”) C: 54.
55 H: 7.82 N : 17.37実施例4
5
4−プロパノイル−1−(2−ピロリドン−5〜カルボ
ニル)ピペラジン:
融点138〜139℃
元素分析値(C121N303として)計算値(%”)
C: 56.90 H: 7.56 N : 1
6.59実測値(%”) C: 56.76 H:
7.78 N : 16.53実施例46
4−カルボベンゾキシ−1−(2−ピロリドン−5−カ
ルボニル)ピペラジン:
融点162〜164℃
元素分析値(C凰?H2鳳N304として)計算値(%
) C: 61.62 H: 6.39 N :
12.68実測値(%) C: 61.46 H:
6.46 N : 12.56実施例47
4−シンナモイル−1−(2−ピロリドン−5−カルボ
ニル)ピペラジン:
融点229〜233℃(分解)
元素分析値(C1?H21N303として)計算値(%
) C: 66.04 H: 6.47 N :
12.84実測値(%) C: 65.83 H:
6.61 N : 13.12実施例48
4−(4−メチルシンナモイル) −1−(2−ピロリ
ドン−5−カルボニル)ピペラジン:
融点253.5〜255.5℃(分解)元素分析値(C
I9 H23N 303として)計算値(%) C:
66.84 H: 6.79 N 712.31実
測値(%”) C: 66.73 H: 6.91
N : 12.26実施例49
4−(4−メトキシシンナモイル)−1−(2−ピロリ
ドン−5−カルボニル)ピペラジン:
融点204〜231℃
元素分析値(C13H2ON204として)計算値(%
) C: 63.85 H: 6.49 N ?
11.76実測値(%’) C: 63.94 H:
6.59 N : 11.76実施例50
4−(N、N−ジメチルカルバモイル”) −’1−
(2−ピロリドン−5−カルボニル)ピペラジン:融点
178.5〜179.5℃
元素分析値(C12H2QN403として)計算値(%
) C: 53.72 H: 7.51 N 72
0.88実測値(%) C: 53.61 H:
7.79 N : 20.71実施例51
4−イソプロピルアミノカルボニルメチル−1−(2−
ピロリドン−5−カルボニル)ピペラジン:融点125
〜127℃
元素分析値(C13H2ON203として)計算値(%
’) C+ 56.74 H: 8.16 N :
18.90実測値(%) C: 56.54 H:
8.43 N : 18.76実施例52
4−ニコチノイル−1−(2−ピロリドン−5−カルボ
ニル)ピペラジン:
融点199.5〜201.5℃
元素分析値(CISH18N403として)計算値(%
”) C: 59.59 H: 6.00 N ?
18.53実測値(%) C: 59.31 H
: 6.01 N F 18.32実施例53
1−(2−ピロリドン−5−カルボニル) −4−(2
−チェノイル)ピペラジン:
融点170.5〜172.5℃
元素分析値(C14HIT N 303 Sとして)計
算値(%”) C: 54.71 H: 5.57
N : 13.67実測値(%) C: 54.6
2 H: 5.56 N ? 13.80実施例54
4−(2−ピリジル”) −1−(2−ピロリドン−5
−カルボニル)ピペラジン:
融点211〜212.5℃
元素分析値(CnH+sN+02として)計算値(%)
C: 61.30 H: 6.61 N : 20.
42実測値(%) C: 61.25 H: 6.7
3 N : 20.38実施例55
4−メチル−N−(2−ピロリドン−5−カルボニル)
ピペリジン:
融点107〜109℃
元素分析値(CIl H1llN202として)計算値
(%’) C: 62.83 H: 8.63 N
713.32実測値(%) C:62.40H:8
.90 N:13.17実施例56
4−フェニル−N−(2−ピロリドン−5−カルボニル
)ピペリジン;
融点198〜199℃
元素分析値(C+s H2Q N 202として)計算
値(%) C: 70.56 H: 7.40 N
? 10.29実測値(%) C: 70.68
H: 7.66 N : 10.15実施例57
4−エトキシカルボニル−N−(2−ピロリドン−5−
カルボニル)ピペリジン:
融点158.0〜159.5℃
元素分析値(C13H2ON204として)計算値(%
’) C: 58.19 H: 7.51 N :
10.44実測値(%) C: 58.18 H:
7.82 N ? 10.44実施例58
4−カルバモイル−N−(2−ピロリドン−5−カルボ
ニル)ピペリジン へミハイドレート:融点172〜1
73℃
元素分析値(ell HI7N303
・zH20として)
計算値(%’) C: 53.22 H: 7.31
N : 16.92実測値(%”) C: 53
.67 )1 : 7.79 N ? 16.76実
施例59
4−ヒドロキシ−N−(2−ピロリドン−5−カルボニ
ル)ピペリジン:
融点147.0〜148.5℃
元素分析値(CIOHI6N203として)計算値(%
) C: 56.59 H: 7.60 N :
13.20実測値(%) C: 56.71 H:
7.94 N ? 13.12実施例6O
N−(2−ピロリドン−5−カルボニル)へキサメチレ
ンイミン:
融点87〜89℃
元素分析値(CIl HI8N202として)計算値(
%) C: 62.83 H: 8.63 N :
13.32実測値(%) C: 62.84 H:
8.92 N 713.39実施例61
4−(2−ピロリドン−5−カルボニル)−2−ケト−
ペラジン:
融点198〜200℃
元素分析値(Cs HI3N303として)計算値(%
”) C: 51.28 H: 6.20 N :
19.89実測値(%) C: 51.21 H:
6.20 N : 19.80実施例62
L−(−)−4−(モルホリノカルボニルメチル)−1
−(2−ピロリドン−5−カルボニル)ピペラジンマレ
イン酸塩:
融点201〜202.5℃
元素分析値(C+sH++N+O+
・C4)1404として)
計算値(%) C: 51.81 H: 6.41
N : 12.72実測値(%) C: 51.6
L H? 6.67 N : 12.73実施例63
4−ピロリジノカルボニルメチル−1−(2−ピロリド
ン−5−カルボニル)ピペラジン:
融点179〜180℃
元素分析値(C1j;H2+N203として)計算値(
%”) C: 58.42 H: 7.84 N
: 18.17実測値(%) C: 5B、26 H
: 8.02 N : 18.06実施例64
4−ピペリジノカルボニルメチル−1−(2−ピロリド
ン−5−カルボニル)ピペラジン:
融点181〜183℃
元素分析値(C+BH2sN403として)計算値(%
)C: 59.61 H: 8.13 N : 17
.38実測値(%) C: 59.46 H: 8.
48 N : 17.23実施例65
4−ヘキシルイミノカルボニルメチル−1−(2−ピロ
リドン−5−カルボニル)ピペラジン:融点143〜1
44℃
元素分析値(CI? H2g N 403として)計算
値(%”) C: 60.69 H: 8.39
N : 16.65実測値(%) C: 80.42
H: 8.45 N 216.45実施例66
4−ジイソプロピルアミノカルボニルメチル−1−(2
−ピロリドン−5−カルボニル)ピペラジン:融点18
9〜190.5℃
元素分析値(CI?83ON40sとして)計算値(%
) C: 60.33 H: 8.93 N :
16.55実測値(%’) C: 60.03 H:
9.24 N : 16.55実施例67
4−モルホリノエチル−1−(2−ピロリドン−5−カ
ルボニル)ピペラジン マレイン@i:融点179〜1
81℃
元素分析値(CIs H26N 403・2C4H40
4・AH20として)
計算値(%) C: 50.09 H: 6.40
N 710.16実測値(%) C: 49.99
H: 6.74 N : 10.22実施例68
4−ピロリジノエチル−1−(2−ピロリドン−5−カ
ルボニル)ピペラジン マレイン酸塩:融点169〜1
70℃
元素分析値(CIs H211N 402・2 C4H
404・%H20として)計算値(%) C: 51
.58 H: 6.59 N : 10.46実測値
(%) C: 51.60 H: 6.90 N
: 10.29実施例69
4−ピペリジノエチル−1−(2−ピロリドン−5−カ
ルボニル)ピペラジン:
融点131〜133℃
元素分析値(CI8H28N402として)計算値(%
) C: 62.31 H: 9.15 N :
18.17実測値(%) C: 61.83 H:
9.16 N : 18.08実施例70
4−ピロリジノアセチル−1−(2−ピロリドン−5−
カルボニル)ピペラジン:
融点166.5〜168.0℃
元素分析値(CIs H24N 403として)計算値
(%) C: 57.58 H: 7.89 N
: 17.91実測値(%’) C: 57.55
H: 8.04 N : 17.99実施例71
4−ピペリジノアセチル−1−(2−ピロリドン−5−
カルボニル)ピペラジン:
融点195〜196℃
元素分析値(C18H23N30sとして)計算値(%
) C: 59.61 H: 8.13 N :
17.38実測値(%) C: 59.16 H:
8.42 N : 17.43実施例72
D−(+)−4−モルホリノカルボニルメチル−°1−
(2−ピロリドン−5−カルボニル)ピペラジン マレ
イン酸塩:
融点199〜201℃
元素分析値(CI28I9N304
・C4H,04として)
計算値(%)C: 51.81 H: 6.41 N
: 12.72実測値(%) C: 51.75
H: 6.29 N : 12.76実施例73
D−(+)−4−エトキシカルボニル−ロリドン−5−
カルボニル)ピペラジン:融点71〜73℃
元素分析値(CI28I9N3 04
・’AH20として)
計算値(%’) C : 52.64 H : 7.
18 N : 15.35実測値(%) C :
52.69 H : 7.26 N : 15.46
実施例74
D− (+)−4−モルホリノアセチル−1−(2−ピ
ロリドン−5−カルボニル)ピペラジン:融点139〜
14L’C
元素分析値(C18H23N3 04
・V4H20として)
計算値(%) C : 54.78 H : 7.5
1 N : 17.04実測値(%) C : 5
4.88 H : 7.66 N : 17.12実
施例75
4−(2−フェノキシエチル) −1− (2−ピロリ
ドン−5−カルボニル)ピペラジン:
融点131.5〜133.0℃
元素分析値( C I? H 23 N 3 0 3と
して)計算値(%) C : 64.33 H :
7.30 N : 13.24実測値(%) C
: 64.38 H : 7.28 N : 13.
29実施例76
4− (2− (4−メチルフェノキシ)エチル)−1
−(2−ピロリドン−5−カルボニル)ピペラジン:融
点146〜147.5℃
元素分析値(C18H2SN303として)計算値(%
) C : 65.24 H : 7.60 N
: 12.68実測値(%) C : 65.26
H : 7.60 N : 12.70実施例77
4−(2− (2−クロロフェノキシ)エチル)−1−
(2−ピロリドン−5−カルボニル)ピペラジン:融
点133〜134℃
元素分析値(CI?H22CIN3 03として)計算
値(%) C : 5B.04 H : 6.30
N : 11.94実測値(%) C : 57.
95 H j 6.30 N : 11.90実施例
7日
D− (+)−4− (4−メチルベンジルピロリドン
−5−カルボニル
融点 71〜73℃
元素分析値( C I? H 23 N 3 0 2
・I20として)計算値(%) C : 63.93
H : 7.89 N : 13.16実測値(%
) C : 63.88 H : 7.92 N
: 13.25実施例79
D− (−)−5−(2−カルバモイル−し−ピロリジ
ノカルボニル)−2−ピロリドン:
融点210〜211.5℃
元素分析値( C 10 H Is N 3 0 3と
して)計算値(%)C : 53.32 H : 6.
71 N : 18.66実測値(%) C :
53.40 H : 6.76 N : 18.74
実施例80
1−(2−ピロリドン−5−カルボニル)−4−チオモ
ルホリノカルボニルメチルピペラジン:融点194〜1
95℃
元素分析値(C18H23N3 03 Sとして)計算
値(%’) C : 52.92 H : 7.11
N : 16.46実測値(%) C : 52
.91 H : 7.10 N : 16.44実施
例81
4−(4−メトキシカルボニルベンジル”) −1−
(2−ピロリドン−5−カルボニル)ピペラジン:融点
113.5〜115.5℃
元素分析値(C18H23N3 04として)計算値(
%) C : 62.59 H : 6.71 N
: 12.1?実測値(%) C : 62.37
H : 6.85 N : 12.15実施例82
4−(2−ヒドロキシエチル)−1−(2−ピロリドン
−5−カルボニル)ピペラジン:
融点129〜131℃
元素分析値(CIl HI9N303とじで)計算値(
%”) C: 54.76 H: 7.94 N
: 17.41実測値(%’) C: 54.67
H: 8.06 N : 17.48実施例83
4−(2−モルホリノカルボニルエチル> −1−<i
−ピロリドン−5−カルボニル)ピペラジン:融点13
5〜136.5℃
元素分析値(C+eH2sN404として)計算値(%
) C: 56.79 H: 7.74 N :
16.56実測値(%) C: 56.59 H:
7.89 N : 16.42実施例84
4− (3−(4−メチルフェノキシ)プロピル)−1
−(2−ピロリドン−5〜カルボニル)ピペラジン:融
点107〜108.5℃
元素分析値(CI982? N 303として)計算値
(%) C: 66.06 H: 7.88 N
: 12.16実測値(%) C: 65.94
H: ’?、96 N S 11.92実施例85
4− (2−(4−メトキシカルボニルフェノキシ)エ
チル) −1−(2−ピロリドン−5−カルボニル)ピ
ペラジン:
融点127〜129℃
元素分析値(C+s H25N 30 sとして)計算
値(%) C: 60.79 H: 6.71 N
711.19実測値(%) C: 60.62 H
: 6.82 N : 11.02実施例86
4− (3−(4−メトキシカルボニルフェノキシ)プ
ロピル) −1−(2−ピロリドン−5−カルボニル)
ピペラジン:
融点141〜142.5℃
元素分析値(C20H2? N 306として)計算値
(%) C: 61.68 H: 7.00 N
: 10.79実測値(%) C: 61.60 H
: 7.13 N : 10.71実施例87
4− (2−(4−ベンジルオキシフェノキシ)エチル
〕−1−(2−ピロリドン−5−カルボニル)ピペラジ
ン:融点110〜112℃
元素分析値(C24H29N 304として)計算値(
%’) C: 68.0?、 H: 6.90 N
: 9.92実測値(%) C:68.OOHニア
、OON :9.96実施例88
4−(3−モルホリノプロピオニル) −1−(2−ピ
ロリドン−5−カルボニル)ピペラジン:
融点184〜185℃
元素分析値(CI8H28N404 ・ZH20とし
て)計算値(%) C: 55.32 H: 7.8
3 N : 16.13実測値(%) C: 55
.65 H: 7.94 N : 16.0B(以下
次頁)
実施例89
4−モルホリノカルボニルメチル−1−(2−ピロリド
ン−5−カルボニル)ホモピペラジン
油状物質。Example 7 4-phenyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 201-202°C Elemental analysis value (as CISH19N302) Calculated value (%
') C: 65.91 H: 7.01 N?
15.37 Actual value (%) C: 65.93 H:
7.08 N? 15.12 Example 8 4-Benzhydryl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 147-148.5°C Elemental analysis value (as C22H25N a O2) Calculated value (%
) C: 72.70 H: 6.93 N 71
1.56 Actual value (%) C: 72.53 H: 7
.. 06 N: 11.32 Example 9 4-(3-chlorophenyl')-1-(2-pyrrolidone-5-a carbonyl)piperazine: Melting point 185.5~
186.5℃ elemental analysis value (C1s) 1+aCIN302
) Calculated value (%') C: 58.54H: 5.8
9 N: 13.65 Actual value (%) C: 58.5
1 H: 5.92 N: 13.77 Example 10 4-(2-chlorophenyl)-1-(2-pyrrolidone-5-carbonyl)piperazine; Melting point 165-167°C
Elemental analysis value (C+5H1sCIN302) Calculated value (%) C: 5B, 54 H: 5.89 N
: 13.65 Actual value (%) C: 58.41 H
: 6.01 N : 13.60 Example 11 4-(4-chlorophenyl)-1-(2-pyrrolidone-
5-carbonyl)piperazine: melting point 244]5-246
.. 5℃ elemental analysis value (as C+5H1sCIN302)
Calculated value (%) C: 5B, 54 H: 5.89
N: 13.65 Actual value (%) C: 58.5
7 H: 5.92 N: 13.67 Example 12 4-(4-fluorophenyl)-1-(2-viroliton-5-carbonyl)piperazine: Melting point 212-213
.. 5℃ elemental analysis value (as C+sH+5FN302) Calculated value (%) C: 61.84 H: 6.23
N: 14.42 Actual value (%) C: 61.77
H: 6.34 N: 14.38 Example 13 4-(2-methylphenyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 212-213
°C Elemental analysis value (as CIBH21N302) Calculated value (
%') C: 66.87 H: 7.37 N
? 14.62 Actual value (%”) C: 66.70
H: 7.50 N: 14.70 Example 14 L-(-)-4-(2-methylphenyl)-1-(2
-pyrrolidone-5-carbonyl)piperazine: melting point 12
2-123.5℃ Elemental analysis value (as C+e H21N s O2) Calculated value (%) C: 66.87 H: 7.37 N
714.62 Actual value (%) C: 66.79 H
: 7.60 N : 14.55 Example 15 1-(2-pyrrolidone-5-carbonyl) -4-(3
-)lifluoromethylphenyl)piperazine: melting point 13
3.5-134.5°C Elemental analysis value (as C+eHteF3Na 02) Calculated value (%) C: 56.30 H: 5.32 N
: 12.31 Actual value (%”) C: 56.59
H: 5.41 N: 12.41 Example 16 4-(2-methoxyphenyl')-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 157-158°C Elemental analysis value (as CI6H21N303) Calculated value (%
') C: 63.35 H: 6.98 N 7
13.85 Actual value (%) C: 63.25 H:
7.07 N: 13.87 Example 17 4-(4-methoxyphenyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 190-192°C Elemental analysis value (as C+e H21N a O3) Calculated value (%) C: 63.35 H: 6.98 N
: 13.85 Actual value (%) C: 63.19
H: 7.22 N: 13.76 Example 18 4-(4-acetylphenyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 227.5-229.0°C Elemental analysis value (as C+tH21N303 )Calculated value(%
) C: 64.74 H: 6.71 N:
13.32 Actual value (%) C: 64.65 H: 6.8
4 N: 13.30 Example 19 4-benzyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 139.5-141.5°C Elemental analysis value (as CI8H21N302) Calculated value (%) C
: 66.88 H: 7.37 N: 14.6
2 Actual measurement value (%) C: 66.60 H: 7.56
N 214.60 Example 20 4-(2-chlorobenzyl)-1-(2-pyrrolidone-5-carbonyl) and perazine: Melting point 92.5-93.
5℃ elemental analysis value (as CI8H20CIN302) Calculated value (%) C: 59.72 H: 6.26
N: 13.06 Actual value (%) C: 59.72
H: 6.32 N: 13.17 Example 21 4-(4-chlorobenzyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 163-165°C
Elemental analysis value (as CI8H20CIN302) Calculated value (%”) C: 59.72 H: 6.26 N
: 13.06 Actual value (%) C: 59.44
H: 6.39 N: 12.80 Example 22 4-(4-fluorobenzyl)-1-(2-pyrrolidone-5-carbonyl) and perazine: Melting point 142-14
3℃ elemental analysis value (as CI8H20FN302) Calculated value (%) C: 62.94 H: 6.60 N
: 13.76 Actual value (%) C: 62.81H:
6.79 N: 13.57 Example 23 4-(4-methylbenzyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 144.5-14
5.5℃ elemental analysis value (CI? H23N 302) calculated value (%) C: 67.75 H: 7.69
N: 13.94 Actual value (%) C: 67
.. 71 H: 7.88 N: 13.94 Example 24 1-(2-pyrrolidone-5-carbonyl)-4-(2-
Trifluoromethylbenzyl) piperazine hemitumarate: Melting point 133.5-135.5℃ Elemental analysis value (CI
? H2OF3N 302・%C4H404) Calculated value (%) C: 55.20 H: 5.36
N: 10.16 Actual value (%) C: 55.0
6 H: 5.38 N: 10.12 Example 25 4-(4-methoxybenzyl')-1-(2-pyro I
J t'non-carbonyl) and perazine: melting point 145
~147℃ Elemental analysis value (CI? As H23N 303) Calculated value (%) C: 64.33 H: 7.3
0 N 713.24 Actual value (%') C: 64
.. 29 H: 7.68 N: 13.21 Example 26 4-(3,4-methylenedioxybenzyl)-1-(2
-pyrrolidone-5-carbonyl)piperazine: melting point 10
9-111℃ Elemental analysis value (CI? H21N 304) Calculated value (%) C: 61.62 H: 6.39 N
: 12.68 Actual value (%) C: 61.67 H
: 6.55 N : 12.63 Example 27 4-benzoyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 173-174°C Elemental analysis value (C
As I6H19N303) Calculated value (%') C:
63.77 H: 6.35 N? 13.94 Actual value (%) C: 63.59 H: 6.49
N: 13.98 Example 28 L (-)-4-benzoyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 113.5-1
15.5°C elemental analysis value (as C OeH+5Na03)
Calculated value (%) C: 63.77 H: 6.35
N: 13.94 Actual value (%') C: 63.
70 H: 6.82 N: 13.95 Example 2
9 4-(2-methylbenzoyl)-1-(2-pyro IJ
l'non--carbonyl)piperazine: melting point 206-2
07℃ elemental analysis value (CI? H2 double N30 double color 303 calculated value (%) C: 64.74 H: 6.71 N
: 13.32 Actual value (%) C: 64.49
H: 6.94 N: 13.09 Example 30 4-(3-methylbenzoyl)-1-(2-pyrrolidone-5-carbonyl) and perazine: Melting point 175-176
.. 5℃ elemental analysis value (as CI7H21N303) Calculated value (%) C: 64.74 H: 6.71 N
: 13.32 Actual value (%') C: 64.49
H: 6.94 N: 13.09 Example 31 4-(4-methylbenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 162-164°C Elemental analysis value (CI? H21N s O3) ) Calculated value (%) C: 64.74 H: 6.71 N
: 13.32 Actual value (%) C: 64.41
H: 6.80 N: 13.24 Example 32 4-(2,4-dimethylbenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 213-215°C Elemental analysis value (as CI8H23N303) calculation value(%
') C: 65.63 H: 7.04 N:
12.76 Actual value (%) C: 65.57 H:
7.26 N: 12.77 Example 33 4-(4-methoxybenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 180.5-182.5°C Elemental analysis value (as CI?H21N304) )Calculated value(%
) C: 61.61 H: 6.39 N: 12
.. 68 Actual value (%) C: 61.70 H: 6.
56 N: 12.72 Example 34 1-(2-pyrrolidone-5-carbonyl)-4-(3°4.5-)rimethoxybenzoyl)piperazine: Melting point 170-172°C Elemental analysis value (C+s Hzs N 30 s) Calculated value (%) C: 58.30 H: 6.44
N: 10.74 actual value (%) C: 5B, 2
7 H: 6.59 N? 10.75 Example 35 4-(4-nitrobenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 205.5-207.5°C Elemental analysis value (as CI6HI8N405) Calculated value (%
) C: 55.49 H: 5.24 N:
16.18 Actual value (%) C: 55.33 H:
5.34 N: 16.23 Example 36 4-(4-fluorobenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 195.5-197.5°C (decomposition) Elemental analysis value (C
As I6H18FN303) Calculated value (%) C:
60.18 H: 5.68 N: 13.16 Actual value (%) C: 60.20 H: 5.71
N: 13.20 Example 37 4-(2-chlorobenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 175-177°C Elemental analysis value (as CIeH + aCIN303) Calculated value (%) C: 57 .23H: 5.40N
: 12.51 actual value (%) C: 57.21 H
: 5.46 N : 12.43 Example 38 4-(4-chlorobenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 179-181°C Elemental analysis value (as C electric BHI8CIN3 o3) calculation Value (%) C: 57.23 H: 5.40 N
: 12.51 Actual value (%) C: 56.94
H: 5.54 N: 12.45 Example 39 4-(2,4-dichlorobenzoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 206-208°C Elemental analysis value (C16Hl?c12N 303)
Calculated value (%) C: 51.91 H: 4.63
N: 11.35 Actual value (%) C: 52.0
0 H: 4.63 N: 11.31 Example 40 4-Phenylacetyl-1-(2-pyrrolidone-5-carbonyl) and perazine: Melting point 150.5-152.0°C Elemental analysis value (as C1?H21N303) )Calculated value(%
) C: 84.74 H: 6.71 N:
13.32 Actual value (%”) C: 64.37 H:
6.89 N: 13.28 Example 4 4-(4-methoxyphenylacetyl) -1-(2-
Pyrrolidone-5-carbonyl)piperazine: Melting point 148
.. 5~149.5℃ Elemental analysis value (as C1?H21N304) Calculated value (%
') C: 62.59 H: 6.71 N:
12.17 Actual value (%) C: 62.55 H: 6
.. 90 N: 12.22 Example 42 4-(4-chlorophenylacetyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 185-
187℃ Elemental analysis value (CI?H2OClN303) Calculated value (%”) C: 58.37 H: 5.76 N
: 12.01 Actual value (%) C: 58.50
H: 5.84 N: 12.09 Example 43 4-/Tyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 129-131°C Elemental analysis value (as CIOHI?N3 o2) Calculated value (
%) C: 56.85 H: 8.11 N 7
19.89 Actual value (%) C: 56.85 H:
7.96 N: 19.37 Example 44 4-acetyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 118-123°C Elemental analysis value (as Co H1?N303 ・1/6H20) Calculated value ( %) C: 54.53 H: 7.21
N: 17.34 Actual value (%”) C: 54.
55 H: 7.82 N: 17.37 Example 4
5 4-Propanoyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 138-139°C Elemental analysis value (as C121N303) Calculated value (%”)
C: 56.90 H: 7.56 N: 1
6.59 Actual value (%”) C: 56.76 H:
7.78 N: 16.53 Example 46 4-carbobenzoxy-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 162-164°C Elemental analysis value (as C-o?H2-o-N304) Calculated value ( %
) C: 61.62 H: 6.39 N:
12.68 Actual value (%) C: 61.46 H:
6.46 N: 12.56 Example 47 4-cinnamoyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 229-233°C (decomposition) Elemental analysis value (as C1?H21N303) Calculated value (%
) C: 66.04 H: 6.47 N:
12.84 Actual value (%) C: 65.83 H:
6.61 N: 13.12 Example 48 4-(4-methylcinnamoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 253.5-255.5°C (decomposition) Elemental analysis value ( C
I9 H23N 303) Calculated value (%) C:
66.84 H: 6.79 N 712.31 Actual value (%”) C: 66.73 H: 6.91
N: 12.26 Example 49 4-(4-methoxycinnamoyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 204-231°C Elemental analysis value (as C13H2ON204) Calculated value (%
) C: 63.85 H: 6.49 N?
11.76 Actual value (%') C: 63.94 H:
6.59 N: 11.76 Example 50 4-(N,N-dimethylcarbamoyl") -'1-
(2-pyrrolidone-5-carbonyl)piperazine: Melting point 178.5-179.5℃ Elemental analysis value (as C12H2QN403) Calculated value (%
) C: 53.72 H: 7.51 N 72
0.88 Actual value (%) C: 53.61 H:
7.79 N: 20.71 Example 51 4-isopropylaminocarbonylmethyl-1-(2-
Pyrrolidone-5-carbonyl)piperazine: Melting point 125
~127℃ Elemental analysis value (as C13H2ON203) Calculated value (%
') C+ 56.74 H: 8.16 N:
18.90 Actual value (%) C: 56.54 H:
8.43 N: 18.76 Example 52 4-nicotinoyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 199.5-201.5°C Elemental analysis value (as CISH18N403) Calculated value (%
”) C: 59.59 H: 6.00 N?
18.53 Actual value (%) C: 59.31 H
: 6.01 N F 18.32 Example 53 1-(2-pyrrolidone-5-carbonyl) -4-(2
-chenoyl)piperazine: Melting point 170.5-172.5°C Elemental analysis value (as C14HIT N 303 S) Calculated value (%”) C: 54.71 H: 5.57
N: 13.67 Actual value (%) C: 54.6
2 H: 5.56 N? 13.80 Example 54 4-(2-pyridyl")-1-(2-pyrrolidone-5
-carbonyl)piperazine: Melting point 211-212.5°C Elemental analysis value (as CnH+sN+02) Calculated value (%)
C: 61.30 H: 6.61 N: 20.
42 Actual value (%) C: 61.25 H: 6.7
3N: 20.38 Example 55 4-Methyl-N-(2-pyrrolidone-5-carbonyl)
Piperidine: Melting point 107-109°C Elemental analysis value (as CIl H1llN202) Calculated value (%') C: 62.83 H: 8.63 N
713.32 Actual value (%) C: 62.40H: 8
.. 90 N: 13.17 Example 56 4-phenyl-N-(2-pyrrolidone-5-carbonyl)piperidine; Melting point 198-199°C Elemental analysis value (as C+s H2Q N 202) Calculated value (%) C: 70. 56H: 7.40N
? 10.29 Actual value (%) C: 70.68
H: 7.66 N: 10.15 Example 57 4-ethoxycarbonyl-N-(2-pyrrolidone-5-
Carbonyl) piperidine: Melting point 158.0-159.5℃ Elemental analysis value (as C13H2ON204) Calculated value (%)
') C: 58.19 H: 7.51 N:
10.44 Actual value (%) C: 58.18 H:
7.82 N? 10.44 Example 58 4-Carbamoyl-N-(2-pyrrolidone-5-carbonyl)piperidine hemihydrate: Melting point 172-1
73℃ Elemental analysis value (as ELL HI7N303 zH20) Calculated value (%') C: 53.22 H: 7.31
N: 16.92 Actual value (%”) C: 53
.. 67) 1: 7.79 N? 16.76 Example 59 4-Hydroxy-N-(2-pyrrolidone-5-carbonyl)piperidine: Melting point 147.0-148.5°C Elemental analysis value (as CIOHI6N203) Calculated value (%
) C: 56.59 H: 7.60 N:
13.20 Actual value (%) C: 56.71 H:
7.94 N? 13.12 Example 6O N-(2-pyrrolidone-5-carbonyl)hexamethyleneimine: Melting point 87-89°C Elemental analysis value (as CIl HI8N202) Calculated value (
%) C: 62.83 H: 8.63 N:
13.32 Actual value (%) C: 62.84 H:
8.92 N 713.39 Example 61 4-(2-pyrrolidone-5-carbonyl)-2-keto-
Perazine: Melting point 198-200℃ Elemental analysis value (as Cs HI3N303) Calculated value (%
”) C: 51.28 H: 6.20 N:
19.89 Actual value (%) C: 51.21 H:
6.20 N: 19.80 Example 62 L-(-)-4-(morpholinocarbonylmethyl)-1
-(2-pyrrolidone-5-carbonyl)piperazine maleate: Melting point 201-202.5°C Elemental analysis value (C+sH++N+O+ ・C4) as 1404) Calculated value (%) C: 51.81 H: 6.41
N: 12.72 Actual value (%) C: 51.6
LH? 6.67 N: 12.73 Example 63 4-pyrrolidinocarbonylmethyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 179-180°C Elemental analysis value (C1j; as H2+N203) Calculated value (
%”) C: 58.42 H: 7.84 N
: 18.17 Actual value (%) C: 5B, 26H
: 8.02 N : 18.06 Example 64 4-piperidinocarbonylmethyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 181-183°C Elemental analysis value (as C+BH2sN403) Calculated value (%
) C: 59.61 H: 8.13 N: 17
.. 38 Actual value (%) C: 59.46 H: 8.
48 N: 17.23 Example 65 4-hexyliminocarbonylmethyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 143-1
44℃ Elemental analysis value (CI? H2g N 403) Calculated value (%”) C: 60.69 H: 8.39
N: 16.65 Actual value (%) C: 80.42
H: 8.45 N 216.45 Example 66 4-diisopropylaminocarbonylmethyl-1-(2
-pyrrolidone-5-carbonyl)piperazine: melting point 18
9~190.5℃ Elemental analysis value (as CI?83ON40s) Calculated value (%
) C: 60.33 H: 8.93 N:
16.55 Actual value (%') C: 60.03 H:
9.24 N: 16.55 Example 67 4-morpholinoethyl-1-(2-pyrrolidone-5-carbonyl)piperazine malein@i: Melting point 179-1
81℃ Elemental analysis value (CIs H26N 403・2C4H40
4・AH20) Calculated value (%) C: 50.09 H: 6.40
N 710.16 Actual value (%) C: 49.99
H: 6.74 N: 10.22 Example 68 4-pyrrolidinoethyl-1-(2-pyrrolidone-5-carbonyl)piperazine maleate: Melting point 169-1
70℃ Elemental analysis value (CIs H211N 402・2 C4H
404・%H20) Calculated value (%) C: 51
.. 58 H: 6.59 N: 10.46 Actual value (%) C: 51.60 H: 6.90 N
: 10.29 Example 69 4-piperidinoethyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 131-133°C Elemental analysis value (as CI8H28N402) Calculated value (%
) C: 62.31 H: 9.15 N:
18.17 Actual value (%) C: 61.83 H:
9.16 N: 18.08 Example 70 4-pyrrolidinoacetyl-1-(2-pyrrolidone-5-
Carbonyl) piperazine: Melting point 166.5-168.0°C Elemental analysis value (as CIs H24N 403) Calculated value (%) C: 57.58 H: 7.89 N
: 17.91 Actual value (%') C: 57.55
H: 8.04 N: 17.99 Example 71 4-piperidinoacetyl-1-(2-pyrrolidone-5-
Carbonyl) piperazine: Melting point 195-196℃ Elemental analysis value (as C18H23N30s) Calculated value (%
) C: 59.61 H: 8.13 N:
17.38 Actual value (%) C: 59.16 H:
8.42 N: 17.43 Example 72 D-(+)-4-morpholinocarbonylmethyl-°1-
(2-pyrrolidone-5-carbonyl)piperazine maleate: Melting point 199-201°C Elemental analysis value (as CI28I9N304 ・C4H,04) Calculated value (%) C: 51.81 H: 6.41 N
: 12.72 Actual value (%) C: 51.75
H: 6.29 N: 12.76 Example 73 D-(+)-4-ethoxycarbonyl-lolidone-5-
Carbonyl) piperazine: Melting point 71-73°C Elemental analysis value (as CI28I9N304/'AH20) Calculated value (%') C: 52.64 H: 7.
18 N: 15.35 Actual value (%) C:
52.69 H: 7.26 N: 15.46
Example 74 D- (+)-4-morpholinoacetyl-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 139-
14L'C Elemental analysis value (as C18H23N3 04 ・V4H20) Calculated value (%) C: 54.78 H: 7.5
1 N: 17.04 Actual value (%) C: 5
4.88 H: 7.66 N: 17.12 Example 75 4-(2-phenoxyethyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 131.5-133.0°C Elemental analysis value (As C I? H 23 N 3 0 3) Calculated value (%) C: 64.33 H:
7.30 N: 13.24 Actual value (%) C
: 64.38 H: 7.28 N: 13.
29 Example 76 4-(2-(4-methylphenoxy)ethyl)-1
-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 146-147.5°C Elemental analysis value (as C18H2SN303) Calculated value (%
) C: 65.24 H: 7.60 N
: 12.68 Actual value (%) C: 65.26
H: 7.60 N: 12.70 Example 77 4-(2-(2-chlorophenoxy)ethyl)-1-
(2-pyrrolidone-5-carbonyl)piperazine: Melting point 133-134°C Elemental analysis value (as CI?H22CIN303) Calculated value (%) C: 5B. 04H: 6.30
N: 11.94 Actual value (%) C: 57.
95 H j 6.30 N: 11.90 Example 7th D- (+)-4- (4-Methylbenzylpyrrolidone-5-carbonyl Melting point 71-73°C Elemental analysis value (CI? H 23 N 3 0 2
・As I20) Calculated value (%) C: 63.93
H: 7.89 N: 13.16 Actual value (%
) C: 63.88 H: 7.92 N
: 13.25 Example 79 D-(-)-5-(2-carbamoyl-pyrrolidinocarbonyl)-2-pyrrolidone: Melting point 210-211.5°C Elemental analysis value (C10H Is N303 ) Calculated value (%) C: 53.32 H: 6.
71 N: 18.66 Actual value (%) C:
53.40 H: 6.76 N: 18.74
Example 80 1-(2-pyrrolidone-5-carbonyl)-4-thiomorpholinocarbonylmethylpiperazine: melting point 194-1
95℃ Elemental analysis value (as C18H23N303S) Calculated value (%') C: 52.92 H: 7.11
N: 16.46 Actual value (%) C: 52
.. 91 H: 7.10 N: 16.44 Example 81 4-(4-methoxycarbonylbenzyl") -1-
(2-pyrrolidone-5-carbonyl)piperazine: Melting point 113.5-115.5℃ Elemental analysis value (as C18H23N304) Calculated value (
%) C: 62.59 H: 6.71 N
: 12.1? Actual value (%) C: 62.37
H: 6.85 N: 12.15 Example 82 4-(2-hydroxyethyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 129-131°C Elemental analysis value (CIl HI9N303 binding) calculation value(
%”) C: 54.76 H: 7.94 N
: 17.41 Actual value (%') C: 54.67
H: 8.06 N: 17.48 Example 83 4-(2-morpholinocarbonylethyl>-1-<i
-pyrrolidone-5-carbonyl)piperazine: melting point 13
5 to 136.5℃ Elemental analysis value (as C+eH2sN404) Calculated value (%
) C: 56.79 H: 7.74 N:
16.56 Actual value (%) C: 56.59 H:
7.89 N: 16.42 Example 84 4-(3-(4-methylphenoxy)propyl)-1
-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 107-108.5°C Elemental analysis value (CI982?N303) Calculated value (%) C: 66.06 H: 7.88 N
: 12.16 Actual value (%) C: 65.94
H: '? , 96 N S 11.92 Example 85 4-(2-(4-methoxycarbonylphenoxy)ethyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 127-129°C Elemental analysis value (C+s H25N 30 s) Calculated value (%) C: 60.79 H: 6.71 N
711.19 Actual value (%) C: 60.62 H
: 6.82 N : 11.02 Example 86 4- (3-(4-methoxycarbonylphenoxy)propyl) -1-(2-pyrrolidone-5-carbonyl)
Piperazine: Melting point 141-142.5°C Elemental analysis value (C20H2?N 306) Calculated value (%) C: 61.68 H: 7.00 N
: 10.79 Actual value (%) C: 61.60 H
: 7.13 N : 10.71 Example 87 4-(2-(4-benzyloxyphenoxy)ethyl]-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 110-112°C Elemental analysis value (C24H29N 304) calculated value (
%') C: 68.0? , H: 6.90N
: 9.92 Actual value (%) C: 68. OOH near, OON: 9.96 Example 88 4-(3-morpholinopropionyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 184-185°C Elemental analysis value (as CI8H28N404 ・ZH20) Calculated value ( %) C: 55.32 H: 7.8
3 N: 16.13 Actual value (%) C: 55
.. 65 H: 7.94 N: 16.0B (following next page) Example 89 4-morpholinocarbonylmethyl-1-(2-pyrrolidone-5-carbonyl) homopiperazine oil.
元素分析値(C+s H28N 404として)計算値
(%) C: 56.79 H: 7.74 N
: 16.56実測値(%’) C: 56.83
H: 7.62 N 716.57実施例9O
N−(2−ピロリドン−5−カルボニル) −1,2,
3,4−テトラヒドロイソキノリン
融点153〜155℃。Elemental analysis value (as C+s H28N 404) Calculated value (%) C: 56.79 H: 7.74 N
: 16.56 Actual value (%') C: 56.83
H: 7.62 N 716.57 Example 9O N-(2-pyrrolidone-5-carbonyl) -1,2,
3,4-tetrahydroisoquinoline melting point 153-155°C.
元素分析値(CI4HI6N202として)計算値(%
) C: 68.83 H: 6.60 N ?
11.47実測値(%) C: 68.968 :
6.56 N : 11.53実施例91
4−アセトアミド−1−(2−ピロリドン−5−カルボ
ニル)ピペラジン: 融点234.5〜236℃。Elemental analysis value (as CI4HI6N202) Calculated value (%
) C: 68.83 H: 6.60 N?
11.47 Actual value (%) C: 68.968:
6.56 N: 11.53 Example 91 4-acetamido-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 234.5-236°C.
元素分析値(CI2HI9N303として)計算値(%
”) C: 56.90 H: 7.56 N :
16.59実測値(%”) C: 56.76 H
: 7.74 N : 16.63実施例92
4−(4−ペンジロキシオルボニルビベラジノ力ルポニ
ルメチル) −1−(2−ピロリドン−5−カルボニル
)ピペラジン: 融点171〜174℃。Elemental analysis value (as CI2HI9N303) Calculated value (%
”) C: 56.90 H: 7.56 N:
16.59 Actual value (%”) C: 56.76 H
: 7.74 N : 16.63 Example 92 4-(4-Pendyloxyorbonylbiverazinolpylmethyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 171-174°C.
元素分析値(C23H31NS osとして)計算値(
%) C: 60.38 H: 6.83 N :
15.31実測値(%) C: 60.14 H:
7.12 N : 15.09実施例93
4−ピペラジノカルボニルメチル−1−(2−とロリP
ンー5−カルボニル)ピペラジン マレイン酸塩:融点
142〜144℃。Elemental analysis value (as C23H31NS os) Calculated value (
%) C: 60.38 H: 6.83 N:
15.31 Actual value (%) C: 60.14 H:
7.12 N: 15.09 Example 93 4-piperazinocarbonylmethyl-1-(2- and LoliP
-5-carbonyl)piperazine maleate: melting point 142-144°C.
元素分析値(C19H2?N303 ・ca H,o
a ・ 1/4 H20として)計算値(%) C
: 49.33 H: 5.98 N : 12.5
1実測値(%) C: 49.28 H: 5.99
N : 12.46実施例94
4− (4−(4−メチルベンジル)ピペラジノカルボ
ニルメチル) −1−(2−ピロリドン−5−カルボニ
ル)ピペラジン : 融点168〜170.5℃。Elemental analysis value (C19H2?N303 ・ca H, o
a ・1/4 H20) Calculated value (%) C
: 49.33 H: 5.98 N: 12.5
1 Actual value (%) C: 49.28 H: 5.99
N: 12.46 Example 94 4-(4-(4-methylbenzyl)piperazinocarbonylmethyl)-1-(2-pyrrolidone-5-carbonyl)piperazine: Melting point 168-170.5°C.
元素分析値(C23H33N s O3として)計算値
(%) C: 64.61 H: 7.78 N
716.38実測値(%) C: 64.55 H:
7.87 N : 16.24実施例95
4− (3−(4−メチルフェニル)プロピル) −1
−(2−ピロリドン−5−カルボニル)ピペラジン:融
点74〜76℃。Elemental analysis value (as C23H33N s O3) Calculated value (%) C: 64.61 H: 7.78 N
716.38 Actual value (%) C: 64.55 H:
7.87 N: 16.24 Example 95 4- (3-(4-methylphenyl)propyl) -1
-(2-pyrrolidone-5-carbonyl)piperazine: melting point 74-76°C.
元素分析値(C19H2?N302として)計算値(%
) C: 69.27 H: 8.26 N :
12.75実測値(%) C: 69.31 H:
8.14 N : 12.76実施例96
N−(2−ピロリドン−5−カルボニル)ピペラジン−
4−オン: 融点153〜155℃。Elemental analysis value (as C19H2?N302) Calculated value (%
) C: 69.27 H: 8.26 N:
12.75 Actual value (%) C: 69.31 H:
8.14 N: 12.76 Example 96 N-(2-pyrrolidone-5-carbonyl)piperazine-
4-one: Melting point 153-155°C.
元素分析値(C1(lH14N203として)計算値(
%) C: 57.13 H: 6.71 N 7
13.32実測値(%) C: 56.94 H:
6.61 N : 13.03実施例97
D−(+) −4−モルホリノカルボニルメチル−1−
(2−ピロリドン−5−カルボニル)ピペラジン:融点
129〜129.5℃。Elemental analysis value (C1 (as lH14N203) calculated value (
%) C: 57.13 H: 6.71 N 7
13.32 Actual value (%) C: 56.94 H:
6.61 N: 13.03 Example 97 D-(+)-4-morpholinocarbonylmethyl-1-
(2-pyrrolidone-5-carbonyl)piperazine: melting point 129-129.5°C.
元素分析値(C19H2?N304 ・%C2850H
として)
計算値(%’) C: 55.32 H: 7.83
N : 16.13実測値(%) C: 55.
48 H: 7.80 N ? 16.26実施例9
8
4−ベンジロキシカルボニル−1−(2−ピロリドン−
5−カルボニル)ホモピペラジン:
融点111〜113℃。Elemental analysis value (C19H2?N304 ・%C2850H
) Calculated value (%') C: 55.32 H: 7.83
N: 16.13 Actual value (%) C: 55.
48H: 7.80N? 16.26 Example 9
8 4-benzyloxycarbonyl-1-(2-pyrrolidone-
5-carbonyl) homopiperazine: Melting point 111-113°C.
元素分析値(C18)123N304として)計算値(
%) C: 62.59 H: 6.71 N :
12.17実測値(%) C: 62.57 H:
6.75 N : 12.20実施例99
4−モルホリノアセチル−1−(2−ピロリドン−5−
カルボニル)ホモピペラジン フマル酸塩:融点148
〜150℃。Elemental analysis value (C18) 123N304) Calculated value (
%) C: 62.59 H: 6.71 N:
12.17 Actual value (%) C: 62.57 H:
6.75 N: 12.20 Example 99 4-morpholinoacetyl-1-(2-pyrrolidone-5-
carbonyl) homopiperazine fumarate: melting point 148
~150℃.
元素分析値(CI6826N404 ・C4H404・
%H20として)
計算値(%) C: 52.34 H: 6.70
N : 12.21実測値(%’) C: 52.
26 H: 6.68 N : 11.99実施例1
00
4−モルホリノカルボニル−1−(2−ピロリドン−5
−カルボニル)ピペラジン:
融点183〜185℃。Elemental analysis value (CI6826N404 ・C4H404・
%H20) Calculated value (%) C: 52.34 H: 6.70
N: 12.21 Actual value (%') C: 52.
26 H: 6.68 N: 11.99 Example 1
00 4-morpholinocarbonyl-1-(2-pyrrolidone-5
-carbonyl)piperazine: Melting point 183-185°C.
元素分析値(C19H2?N304として)計算値(%
”) C: 54.18 H: 7.14 N :
18.05実測値(%) C: 54.07 H:
7.25 N : 17.76実施例101
2− (4−(2−L−カルバモイルピロリジノカルボ
ニルメチル)ピペラジノカルボニル)−D−ピロリジノ
−5−オン: 融点239〜242℃。Elemental analysis value (as C19H2?N304) Calculated value (%
”) C: 54.18 H: 7.14 N:
18.05 Actual value (%) C: 54.07 H:
7.25 N: 17.76 Example 101 2-(4-(2-L-carbamoylpyrrolidinocarbonylmethyl)piperazinocarbonyl)-D-pyrrolidino-5-one: Melting point 239-242°C.
元素分析値(C19H2?N304 ・’A CH3
0HトL テ)
計算値(%) C: 53.94 H: 7.41
N 719.06実測値(%) C: 54.33
H: 7.41 N : 19.11実施例102
4−ピペリジノ−1−(2−ピロリドン−5−カルボニ
ル)ピペリジン: 融点147〜150℃。Elemental analysis value (C19H2?N304 ・'A CH3
0H ToL Te) Calculated value (%) C: 53.94 H: 7.41
N 719.06 Actual value (%) C: 54.33
H: 7.41 N: 19.11 Example 102 4-Piperidino-1-(2-pyrrolidone-5-carbonyl)piperidine: Melting point 147-150°C.
元素分析値(C19H2?N302として)計算値(%
’) C: 64.49 H: 9.02 N :
15.04実測値(%) C: 64.33 H:
8.98 N : 14.97実施例103
D−(+) −4−ベンジロキシカルボニル−1−(2
−ピロリドン−5−カルボニル)ピペラジン:融点49
〜52℃。Elemental analysis value (as C19H2?N302) Calculated value (%
') C: 64.49 H: 9.02 N:
15.04 Actual value (%) C: 64.33 H:
8.98 N: 14.97 Example 103 D-(+)-4-benzyloxycarbonyl-1-(2
-pyrrolidone-5-carbonyl)piperazine: melting point 49
~52℃.
元素分析値(C21H28N404として)計算値(%
’) C; 61.46 H: 6.46 N :
12.56実測値(%) C: 61.30 H:
6.12 N 712.63実施例104
N−(2−ピロリドン−5−カルボニル) −2,6−
シ久−ジメチルピペリジン: 融点177〜181℃。Elemental analysis value (as C21H28N404) Calculated value (%
') C; 61.46 H: 6.46 N:
12.56 Actual value (%) C: 61.30 H:
6.12 N 712.63 Example 104 N-(2-pyrrolidone-5-carbonyl) -2,6-
Dimethylpiperidine: Melting point 177-181°C.
元素分析値(CI2H2ON202として)計算値(%
) C: 64.26 H: 8.99 N :
12.49実測値(%) C: 64.11 H
: 9.11 N : 12.47実施例105
D−(+) −4−チオモルホリノカルボニルメチル−
1−(2−ピロリドン−5−カルボニル)ピペラジンマ
レイン酸塩: 融点159〜161℃。Elemental analysis value (as CI2H2ON202) Calculated value (%
) C: 64.26 H: 8.99 N:
12.49 Actual value (%) C: 64.11 H
: 9.11 N : 12.47 Example 105 D-(+)-4-thiomorpholinocarbonylmethyl-
1-(2-pyrrolidone-5-carbonyl)piperazine maleate: Melting point 159-161°C.
元素分析値(Cps H24N403 S −C4H4
04として)
計算値(%”) C: 49.99 H: 6.18
N ? 12.27実測値(%) C: 49.
84 H: 6.20 8 : 12.28実施例10
6
1−(4−アミノブタノイル)−4−(2−ピロリドン
−5−カルボニル)ピペラジン
融点101〜102℃。Elemental analysis value (Cps H24N403 S -C4H4
04) Calculated value (%”) C: 49.99 H: 6.18
N? 12.27 Actual value (%) C: 49.
84 H: 6.20 8: 12.28 Example 10
6 1-(4-Aminobutanoyl)-4-(2-pyrrolidone-5-carbonyl)piperazine Melting point 101-102°C.
元素分析値(C21H28N403 ・’AHtOとし
て)
計算値(%’I C: 53.59 H: 7.96
N : 19.22実測値(%) C: 53
.75 H: 7.73 N : 18.97実施例
107
1− (4−(N−ベンジロキシカルボニルアミノ)ブ
タノイル)−4−(2−ピロリドン−5−カルボニル)
ピペラジン: 融点157〜159.5℃。Elemental analysis value (as C21H28N403/'AHtO) Calculated value (%'IC: 53.59 H: 7.96
N: 19.22 Actual value (%) C: 53
.. 75 H: 7.73 N: 18.97 Example 107 1-(4-(N-benzyloxycarbonylamino)butanoyl)-4-(2-pyrrolidone-5-carbonyl)
Piperazine: Melting point 157-159.5°C.
元素分析値(C21H28N40Sとして)計算値(%
) C: 60.56 H: 6.78 N :
13.45実測値(%) C: 60.58 H:
6.70 N : 13.42(効果)
以上の結果から明らかなように、本発明化合物はヒトを
含む踊乳動物に対して向知性作用を有し、かつ低毒性な
ので、痴呆の治療薬として有用である。Elemental analysis value (as C21H28N40S) Calculated value (%
) C: 60.56 H: 6.78 N:
13.45 Actual value (%) C: 60.58 H:
6.70 N: 13.42 (Efficacy) As is clear from the above results, the compound of the present invention has a nootropic effect on dancing mammals including humans, and has low toxicity, so it can be used as a therapeutic agent for dementia. Useful.
老人性痴呆の治療薬としてまた精神発育遅滞、脳炎後遺
症、脳性麻痺、脳卒中、脳動脈硬化症、頭部外傷などに
伴う痴呆等の治療薬として用いることができる。It can be used as a therapeutic agent for senile dementia, as well as dementia associated with mental retardation, sequelae of encephalitis, cerebral palsy, stroke, cerebral arteriosclerosis, head trauma, and the like.
Claims (1)
及びその生理学的に許容される塩類。 ▲数式、化学式、表等があります▼〔 I 〕 ここにAは、以下の(a)及び(b)の特徴を有する環
状アミノ基を表わす。 (a)環中に窒素原子以外にヘテロ原子として更に窒素
原子を含んでいるか、又は窒素原子1個のみをヘテロ原
子とする。 (b)無置換のピロリジノ又は無置換のピペリジノでは
ない。[Scope of Claims] A pyroglutamide derivative represented by the following general formula [I] and physiologically acceptable salts thereof. ▲There are mathematical formulas, chemical formulas, tables, etc.▼ [I] Here, A represents a cyclic amino group having the following characteristics (a) and (b). (a) In addition to the nitrogen atom, the ring contains a nitrogen atom as a heteroatom, or only one nitrogen atom is a heteroatom. (b) Not unsubstituted pyrrolidino or unsubstituted piperidino.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1135986 | 1986-01-21 | ||
JP61-11359 | 1986-01-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS62252762A true JPS62252762A (en) | 1987-11-04 |
JP2513197B2 JP2513197B2 (en) | 1996-07-03 |
Family
ID=11775830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61280453A Expired - Lifetime JP2513197B2 (en) | 1986-01-21 | 1986-11-25 | Pyroglutamide derivative |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2513197B2 (en) |
KR (2) | KR870007115A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100515905B1 (en) * | 2000-01-31 | 2005-09-21 | 주식회사 엘지생명과학 | New process for preparing pyrrole amide |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100534523B1 (en) * | 1998-12-23 | 2006-03-16 | 주식회사 코오롱 | Self-settling long fiber nonwovens. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS518266A (en) * | 1974-07-10 | 1976-01-23 | Sakai Chemical Industry Co | Piroridonjudotaino seizohoho |
JPS5210267A (en) * | 1975-07-08 | 1977-01-26 | Ucb Sa | Production of ll pyrogulutamyllll prolineamide and production thereof |
JPS5718611A (en) * | 1980-03-05 | 1982-01-30 | Uni Maiami Za | Angiotensin converting enzyme inhibitor |
JPS5980663A (en) * | 1982-09-04 | 1984-05-10 | フアイザ−・コ−ポレ−シヨン | Dihydropyridines |
JPS59104350A (en) * | 1982-11-10 | 1984-06-16 | フアルムイタリア・カルロ・エルバ・ソシエタ・ペル・アチオ−ニ | Biologically active peptide, manufacture, veterinary composition, animal feed and animal growth stimulating method |
JPS60156700A (en) * | 1983-12-23 | 1985-08-16 | ポリフアルマ ソチエタ ペル アツイオニ | Tripeptide compound, manufacture and medicinal composition |
-
1986
- 1986-11-25 JP JP61280453A patent/JP2513197B2/en not_active Expired - Lifetime
-
1987
- 1987-01-21 KR KR870000435A patent/KR870007115A/en not_active Application Discontinuation
- 1987-07-01 KR KR1019870007055A patent/KR950007591B1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS518266A (en) * | 1974-07-10 | 1976-01-23 | Sakai Chemical Industry Co | Piroridonjudotaino seizohoho |
JPS5210267A (en) * | 1975-07-08 | 1977-01-26 | Ucb Sa | Production of ll pyrogulutamyllll prolineamide and production thereof |
JPS5718611A (en) * | 1980-03-05 | 1982-01-30 | Uni Maiami Za | Angiotensin converting enzyme inhibitor |
JPS5980663A (en) * | 1982-09-04 | 1984-05-10 | フアイザ−・コ−ポレ−シヨン | Dihydropyridines |
JPS59104350A (en) * | 1982-11-10 | 1984-06-16 | フアルムイタリア・カルロ・エルバ・ソシエタ・ペル・アチオ−ニ | Biologically active peptide, manufacture, veterinary composition, animal feed and animal growth stimulating method |
JPS60156700A (en) * | 1983-12-23 | 1985-08-16 | ポリフアルマ ソチエタ ペル アツイオニ | Tripeptide compound, manufacture and medicinal composition |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100515905B1 (en) * | 2000-01-31 | 2005-09-21 | 주식회사 엘지생명과학 | New process for preparing pyrrole amide |
Also Published As
Publication number | Publication date |
---|---|
JP2513197B2 (en) | 1996-07-03 |
KR890001977A (en) | 1989-04-07 |
KR950007591B1 (en) | 1995-07-12 |
KR870007115A (en) | 1987-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI242004B (en) | 1-(1-substituted-4-piperidinyl)methyl-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds | |
US3577440A (en) | 1-substituted-3-amido-pyrrolidines | |
US5073671A (en) | 1-(benzyl or pyridylmethyl)-4 or 5-aminomethyl-pyrrolidin-2-ones | |
SK142399A3 (en) | Indazole amide compounds as serotoninergic agents | |
EP0422485A2 (en) | Quinolone carboxylic acid derivatives, process for their preparation and their use | |
NL8700119A (en) | PYROGLUTAMIDE DERIVATIVES, NOTROPICAL MEDICINAL PRODUCT CONTAINING SPECIFIC PYROGLUTAMIDE DERIVATIVES, SPECIFIC PYROGLUTAMIDE DERIVATIVES AND METHOD FOR PREPARING THESE LASTS. | |
US4207327A (en) | N-(4-Pyrazolidinyl)benzamides and their amino precursors | |
EP0029707B1 (en) | Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them | |
US5332735A (en) | Compounds of N-benzoylpyroline | |
US4857528A (en) | Substituted pyrrolidinones, pharmaceutical compositions and use | |
CZ20032342A3 (en) | Peptide-deformylase inhibitors | |
US3983239A (en) | Hexahydro-γ-carboline derivatives and their salts | |
JPH01131145A (en) | Novel amidino derivative | |
AU624978B2 (en) | N,n'-bis(alkoxyalkyl)-pyridine-2,4-dicarboxylic acid diamides, preparation and their use | |
JPS62252762A (en) | Pyroglutamide derivative | |
US5143912A (en) | Tricyclic pyridone derivatives | |
CA1299571C (en) | 2-aminoacetamide pyridinyl derivatives | |
US3970661A (en) | 2-Amino, 5-carbamoyl pyridine compounds | |
AU684812B2 (en) | A useful hemi-hydrate form of a cerebral function enhancing agent | |
US5258387A (en) | Tricyclic pyridone derivatives | |
WO2005092865A1 (en) | Antiviral 4-aminocarbonylamino-substituted imidazole compound | |
US3970663A (en) | Certain amino-nicotinamide derivatives | |
US3631037A (en) | 1-substituted-2 5-diphenylpyrroles | |
US4328223A (en) | 2-Amino-3a,4,5,6-tetrahydro-perimidine derivatives and their medicinal use in combatting circulatory diseases | |
JPH01221379A (en) | Azaspiro compound |